WO2022021639A1 - Traditional chinese medicine composition for invigorating spleen and activating yang, and use thereof - Google Patents
Traditional chinese medicine composition for invigorating spleen and activating yang, and use thereof Download PDFInfo
- Publication number
- WO2022021639A1 WO2022021639A1 PCT/CN2020/124369 CN2020124369W WO2022021639A1 WO 2022021639 A1 WO2022021639 A1 WO 2022021639A1 CN 2020124369 W CN2020124369 W CN 2020124369W WO 2022021639 A1 WO2022021639 A1 WO 2022021639A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- parts
- diabetes
- spleen
- chinese medicine
- yang
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract description 63
- 210000000952 spleen Anatomy 0.000 title claims abstract description 57
- 239000000203 mixture Substances 0.000 title claims abstract description 25
- 230000003213 activating effect Effects 0.000 title claims abstract description 10
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 63
- 208000020832 chronic kidney disease Diseases 0.000 claims abstract description 25
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims abstract description 20
- 208000033679 diabetic kidney disease Diseases 0.000 claims abstract description 20
- 241000756943 Codonopsis Species 0.000 claims abstract description 16
- 241000336291 Cistanche deserticola Species 0.000 claims abstract description 6
- 241000132012 Atractylodes Species 0.000 claims description 29
- 206010062717 Increased upper airway secretion Diseases 0.000 claims description 22
- 208000026435 phlegm Diseases 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 238000005728 strengthening Methods 0.000 claims description 16
- 241000234314 Zingiber Species 0.000 claims description 15
- 235000006886 Zingiber officinale Nutrition 0.000 claims description 15
- 235000008397 ginger Nutrition 0.000 claims description 15
- 229940079593 drug Drugs 0.000 claims description 14
- 239000000284 extract Substances 0.000 claims description 14
- 241000209020 Cornus Species 0.000 claims description 13
- 241000304195 Salvia miltiorrhiza Species 0.000 claims description 13
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims description 13
- 241000005787 Cistanche Species 0.000 claims description 11
- 239000002775 capsule Substances 0.000 claims description 11
- 244000046146 Pueraria lobata Species 0.000 claims description 8
- 235000010575 Pueraria lobata Nutrition 0.000 claims description 8
- 239000003826 tablet Substances 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000007799 cork Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 abstract description 41
- 239000008280 blood Substances 0.000 abstract description 41
- 230000007812 deficiency Effects 0.000 abstract description 22
- 208000024891 symptom Diseases 0.000 abstract description 16
- 210000002700 urine Anatomy 0.000 abstract description 12
- 210000003414 extremity Anatomy 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 8
- 230000027939 micturition Effects 0.000 abstract description 5
- 206010012735 Diarrhoea Diseases 0.000 abstract description 4
- 206010013781 dry mouth Diseases 0.000 abstract description 4
- 210000003127 knee Anatomy 0.000 abstract description 4
- 206010033799 Paralysis Diseases 0.000 abstract description 3
- 239000011248 coating agent Substances 0.000 abstract description 3
- 238000000576 coating method Methods 0.000 abstract description 3
- 201000001881 impotence Diseases 0.000 abstract description 3
- 206010047513 Vision blurred Diseases 0.000 abstract description 2
- 208000019790 abdominal distention Diseases 0.000 abstract description 2
- 206010016256 fatigue Diseases 0.000 abstract description 2
- 210000001624 hip Anatomy 0.000 abstract description 2
- 206010029446 nocturia Diseases 0.000 abstract description 2
- 206010036067 polydipsia Diseases 0.000 abstract description 2
- 235000003143 Panax notoginseng Nutrition 0.000 abstract 1
- 241000180649 Panax notoginseng Species 0.000 abstract 1
- 206010036790 Productive cough Diseases 0.000 abstract 1
- 208000005946 Xerostomia Diseases 0.000 abstract 1
- 206010003549 asthenia Diseases 0.000 abstract 1
- 208000011318 facial edema Diseases 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 208000014987 limb edema Diseases 0.000 abstract 1
- 208000024794 sputum Diseases 0.000 abstract 1
- 210000003802 sputum Anatomy 0.000 abstract 1
- 210000002784 stomach Anatomy 0.000 description 21
- 208000031971 Yin Deficiency Diseases 0.000 description 16
- 208000011580 syndromic disease Diseases 0.000 description 16
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 230000008506 pathogenesis Effects 0.000 description 13
- 201000010099 disease Diseases 0.000 description 12
- 210000003734 kidney Anatomy 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 238000011160 research Methods 0.000 description 10
- 208000031975 Yang Deficiency Diseases 0.000 description 9
- 230000004069 differentiation Effects 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 230000017531 blood circulation Effects 0.000 description 7
- 230000036772 blood pressure Effects 0.000 description 7
- 229940109239 creatinine Drugs 0.000 description 7
- 230000002485 urinary effect Effects 0.000 description 7
- 102000009027 Albumins Human genes 0.000 description 6
- 108010088751 Albumins Proteins 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 241000219780 Pueraria Species 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 230000002218 hypoglycaemic effect Effects 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 230000006378 damage Effects 0.000 description 5
- 230000003907 kidney function Effects 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 230000035922 thirst Effects 0.000 description 5
- 210000001015 abdomen Anatomy 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 230000008030 elimination Effects 0.000 description 4
- 238000003379 elimination reaction Methods 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 210000001835 viscera Anatomy 0.000 description 4
- 206010010071 Coma Diseases 0.000 description 3
- 208000001380 Diabetic Ketoacidosis Diseases 0.000 description 3
- 241001072909 Salvia Species 0.000 description 3
- 235000017276 Salvia Nutrition 0.000 description 3
- 208000032023 Signs and Symptoms Diseases 0.000 description 3
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 3
- 230000003712 anti-aging effect Effects 0.000 description 3
- 230000003276 anti-hypertensive effect Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000035622 drinking Effects 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 238000007726 management method Methods 0.000 description 3
- 230000000291 postprandial effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 2
- 102000012192 Cystatin C Human genes 0.000 description 2
- 108010061642 Cystatin C Proteins 0.000 description 2
- 208000008960 Diabetic foot Diseases 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- 206010014418 Electrolyte imbalance Diseases 0.000 description 2
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 2
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- 206010021518 Impaired gastric emptying Diseases 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 206010061245 Internal injury Diseases 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- 208000019914 Mental Fatigue Diseases 0.000 description 2
- 235000002791 Panax Nutrition 0.000 description 2
- 241000208343 Panax Species 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 206010038923 Retinopathy Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 229940126678 chinese medicines Drugs 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 235000017803 cinnamon Nutrition 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 210000002468 fat body Anatomy 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 208000001288 gastroparesis Diseases 0.000 description 2
- 230000024924 glomerular filtration Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 230000000422 nocturnal effect Effects 0.000 description 2
- 230000001151 other effect Effects 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 238000002636 symptomatic treatment Methods 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- PAFLSMZLRSPALU-MRVPVSSYSA-N (2R)-3-(3,4-dihydroxyphenyl)lactic acid Chemical compound OC(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-MRVPVSSYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 1
- FBMORZZOJSDNRQ-GLQYFDAESA-N Atractylenolide III Chemical compound C=C([C@@H]1C2)CCC[C@]1(C)C[C@@]1(O)C2=C(C)C(=O)O1 FBMORZZOJSDNRQ-GLQYFDAESA-N 0.000 description 1
- 241000132011 Atractylodes lancea Species 0.000 description 1
- 241000092665 Atractylodes macrocephala Species 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 241000007126 Codonopsis pilosula Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- PAFLSMZLRSPALU-QMMMGPOBSA-N Danshensu Natural products OC(=O)[C@@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-QMMMGPOBSA-N 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 102000015781 Dietary Proteins Human genes 0.000 description 1
- 108010010256 Dietary Proteins Proteins 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010015137 Eructation Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 206010027525 Microalbuminuria Diseases 0.000 description 1
- 241000122904 Mucuna Species 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000025584 Pericardial disease Diseases 0.000 description 1
- 206010034568 Peripheral coldness Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 241000972672 Phellodendron Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000001280 Prediabetic State Diseases 0.000 description 1
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 description 1
- 206010041052 Sluggishness Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930183118 Tanshinone Natural products 0.000 description 1
- 208000005448 Trichomonas Infections Diseases 0.000 description 1
- 206010044620 Trichomoniasis Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000947 anti-immunosuppressive effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000000467 autonomic pathway Anatomy 0.000 description 1
- 230000008721 basement membrane thickening Effects 0.000 description 1
- 208000027687 belching Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 239000000571 coke Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- -1 decoction Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 235000021245 dietary protein Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- 150000004141 diterpene derivatives Chemical class 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000225 effect on diabetes Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 210000000585 glomerular basement membrane Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940125698 hormone suppressant Drugs 0.000 description 1
- 239000008738 huangbai Substances 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000020905 low-protein-diet Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940046781 other immunosuppressants in atc Drugs 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000021075 protein intake Nutrition 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000032253 retinal ischemia Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/40—Cornaceae (Dogwood family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/64—Orobanchaceae (Broom-rape family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
Definitions
- the invention relates to the field of traditional Chinese medicine formulations, in particular to a traditional Chinese medicine composition for strengthening the spleen and activating yang.
- Diabetes is a common and frequently-occurring disease in clinical practice.
- Prof. Ning Guang's team surveyed the prevalence of diabetes and prediabetes among people over 18 years old in China, reaching 11.6% and 50.1%, respectively.
- the prevalence of diabetes in my country is increasing year by year, especially in recent years, the prevalence rate has risen sharply, the development trend is not optimistic, and the incidence has changed.
- Epidemiological data show that more than 80% of diabetics are obese in my country.
- Diabetes modern Chinese medicine mostly belongs to the category of "diabetes” in Chinese medicine.
- “Thirsty and desire” means “dry mouth and desire to drink”.
- this disease name is a generalization of patients with similar symptoms.
- Ancient physicians formed various theories when discussing the pathogenesis of diabetes mellitus.
- Physicians of past dynasties have enriched and developed the pathogenesis of the disease, including the theory of yin deficiency and dryness, the theory of three eliminations, the theory of liver stagnation and qi stagnation, and the theory of blood stasis. Dispelling and other pathogenesis understanding.
- the object of the present invention is to provide a traditional Chinese medicine composition for strengthening spleen and yang yang, which has exact curative effect, and has the effects of synchronizing the spleen and kidney, tonifying yin and yang, promoting blood circulation and removing blood stasis, resolving phlegm and reducing turbidity. It can be used concurrently, well-matched, and the characteristics of the principles and methods are obvious.
- Another object of the present invention is to apply the above-mentioned Chinese medicinal composition for strengthening the spleen and clearing the yang in the preparation of medicines for the treatment of diabetes, diabetic nephropathy and chronic renal insufficiency.
- a kind of traditional Chinese medicine composition for strengthening the spleen and activating yang is characterized in that: by weight, the formula is made up of the following components: 12-18 parts of pueraria, 12-18 parts of Salvia miltiorrhiza, 25- 35 parts, Codonopsis 25-35 parts, Treats 4-6 parts, Chuanxiong 12-18 parts, Tian Qi 8-12 parts, Guizhi 8-12 parts, Xianlingpi 12-18 parts, Cistanche deserticola 25-35 parts, Dogwood 12-18 servings, 8-12 servings of dried ginger, and 12-18 servings of Atractylodes.
- the formula is composed of the following components: 14-16 parts of Pueraria, 14-16 parts of Salvia, 28-32 parts of Atractylodes, 28-32 parts of Codonopsis, 4-6 parts of Treats, 14-16 parts of Chuanxiong parts, 9-11 parts of Tianqi, 9-11 parts of Guizhi, 14-16 parts of Xianlingpi, 28-32 parts of Cistanche deserticola, 14-16 parts of dogwood, 9-11 parts of dried ginger, and 14-16 parts of Atractylodes.
- the formula is made up of the following components: 15 parts of Pueraria lobata, 15 parts of Salvia miltiorrhiza, 30 parts of Atractylodes Rhizoma, 30 parts of Codonopsis Radix, 5 parts of Treats, 15 parts of Chuanxiong, 10 parts of Tianqi, 10 parts of Guizhi , 15 copies of Xianlingpi, 30 copies of Cistanche, 15 copies of dogwood, 10 copies of dried ginger, and 15 copies of Atractylodes.
- the medicine is decoction, granule, tablet, capsule, oral liquid or pill.
- the medicine is a preparation prepared by using the extract of the components in the formula of the Chinese medicine composition for strengthening the spleen and removing yang as the active ingredient, and adding medicinal excipients.
- the extract is a water extract.
- Said diabetes is the late stage of diabetes.
- the diabetes, diabetic nephropathy and chronic renal insufficiency are phlegm-type diabetes, diabetic nephropathy and chronic renal insufficiency.
- the present invention is a formula for "treatment of diabetes from the spleen and stomach".
- Polydipsia mental fatigue, fullness of the abdomen and abdomen, chills, cold limbs, dark complexion, weak waist and knees, limb paralysis, blurred vision, frequent urination, increased nocturnal urination, turbidity, impotence, swollen face or swollen limbs, Diarrhea, pale tongue, fat body, white and dry coating, thin and weak pulse, etc.
- Diabetes, diabetic nephropathy, chronic renal insufficiency, etc. have obvious curative effect after taking the medicine.
- the invention is a traditional Chinese medicine composition for strengthening the spleen and activating yang, which is characterized in that: calculated in parts by weight, the formula is composed of the following components: 12-18 parts of Pueraria lobata, 12-18 parts of Salvia miltiorrhiza, 25-35 parts of Atractylodes Rhizoma, 25-35 parts of Codonopsis Radix. 35 parts, 4-6 parts of Cork, 12-18 parts of Chuanxiong, 8-12 parts of Tianqi, 8-12 parts of Guizhi, 12-18 parts of Xianlingpi, 25-35 parts of Cistanche, 12-18 parts of dogwood, dried Ginger 8-12 parts, Atractylodes 12-18 parts.
- the formula is composed of the following components: 14-16 parts of Pueraria, 14-16 parts of Salvia, 28-32 parts of Atractylodes, 28-32 parts of Codonopsis, 4-6 parts of Treats, 14-16 parts of Chuanxiong parts, 9-11 parts of Tianqi, 9-11 parts of Guizhi, 14-16 parts of Xianlingpi, 28-32 parts of Cistanche deserticola, 14-16 parts of dogwood, 9-11 parts of dried ginger, and 14-16 parts of Atractylodes.
- the formula is made up of the following components: 15 parts of Pueraria lobata, 15 parts of Salvia miltiorrhiza, 30 parts of Atractylodes Rhizoma, 30 parts of Codonopsis Radix, 5 parts of Treats, 15 parts of Chuanxiong, 10 parts of Tianqi, 10 parts of Guizhi , 15 copies of Xianlingpi, 30 copies of Cistanche, 15 copies of dogwood, 10 copies of dried ginger, and 15 copies of Atractylodes.
- the diabetes is the late stage of diabetes and its complications.
- the medicament can be in oral dosage forms such as decoction, granule, tablet, capsule, oral liquid or pill.
- the medicine is a corresponding preparation prepared by using the extracts of the components in the formula of the Chinese medicine composition for strengthening the spleen and removing the yang as active ingredients, and adding pharmaceutical excipients of corresponding dosage forms according to the existing general process.
- the extract is a water extract.
- the formula of the present invention comes from the theoretical system of the inventor's "Treatment of Diabetes from the Spleen and Stomach", and it is believed that the pathogenesis of diabetes is: "The spleen and stomach are out of balance, the things are not naturalized, the subtleties are not transported, and the organs are out of nourishment", so the treatment is to reconcile the spleen and stomach, attack and supplement both Shi is the core.
- spleen deficiency is often manifested as stagnation and heat, and blood stasis is present.
- both yin and yang deficiency are mostly manifested.
- the symptoms of diabetes mellitus are mainly consumption of more food, dry mouth and more drinking.
- the metabolism, transportation and transformation of diet are most closely related to the spleen and stomach. So, how is water metabolized into the human body?
- “Plain Questions: The Differentiation of Meridians” says: “Drinking enters the stomach, escaping the essence and qi, and transporting it upward to the spleen, dispersing the spleen, returning to the lungs, regulating the water channels, and transporting the bladder downward.
- food and water grains enter the human body, decompose through the stomach, metamorphose into the subtle substances, and transport and transform through the spleen to spread the subtle substances throughout the body to support the functional activities of the whole body.
- Diabetes the thirst for a long time, fat, sweet and thick taste, the change of the cream, the internal injury to the spleen and stomach, the spleen deficiency, the phlegm-dampness is endogenous, and the hair is diabetes.
- the spleen and stomach are located in the middle coke, which transports and transforms water and valleys. If the spleen fails to function properly, the spleen cannot disperse the essence, the upper essence cannot be transferred to the lungs, and the lower essence cannot be transported to the bladder, and the viscera cannot be nourished. Damage to the spleen and stomach of the middle burner, passive blood biochemistry, deficiency of qi and blood, and lack of righteousness, not only cause diabetes, but also various syndromes.
- Deficiency syndrome is mainly qi deficiency and yin deficiency.
- Deficiency syndrome is mostly manifested as spleen deficiency and lung heat, spleen deficiency and stomach deficiency, spleen deficiency and liver stagnation. , and develop into a syndrome of yin and yang deficiency or spleen deficiency and collateral obstruction.
- Concurrent syndromes are mostly evidence, mainly stagnation, heat, dampness, phlegm, turbidity, and blood stasis, often caused by multiple evil qi intermingled with each other, or appearing in the entire course of diabetes, or more prominent at a certain stage. Therefore, reconciling the spleen and stomach, attacking and nourishing as the core treatment method, and nourishing the spleen and strengthening the core are the core. In the process of strengthening the righteousness, attention must be paid to exorcising evil spirits.
- Diabetic nephropathy is often complicated by modern diabetic patients in the later stage, which is characterized by deficiency of both yin and yang, mainly yin and yang deficiency of spleen and kidney, and pathogenic factors such as phlegm, turbidity and blood stasis. Some patients with chronic renal insufficiency also show the same syndrome. Aiming at the characteristics of such a disease, treating with the traditional Chinese medicine composition of the present invention has a certain and exact curative effect on diabetes, diabetic nephropathy and chronic renal insufficiency.
- Rhizoma invigorates the spleen and replenishes Qi and dries dampness
- Codonopsis pilosula tonifies the middle and invigorates Qi, so that the central axis can be transported, and they are the monarch medicine. It is combined with Xianlingpi and Cistanche to warm the kidney and help the yang, and they are the minister medicine.
- the whole formula ascends and descends and harmonizes together, combining the functions of spleen and kidney harmony, yin and yang supplementation, promoting blood circulation and removing blood stasis, resolving phlegm and reducing turbidity.
- Atractylodes macrocephala in this recipe can promote the recovery of damaged autonomic nerve function, adjust the balance of human viscera functions, regulate gastrointestinal motility, lower blood sugar, diuresis, and enhance resistance.
- Codonopsis polysaccharide can reduce alloxan-induced diabetes. At the same time, it can improve insulin resistance and insulin sensitivity of the body to a certain extent;
- Xianlingpi has various pharmacological effects such as improving immune function, anti-aging, anti-oxidation, anti-inflammatory, hypoglycemic, and anti-depression.
- Cistanche deserticola has anti-oxidation and anti-aging, neuroprotection, ischemia-reperfusion, improving immunity, protecting the liver and protecting the liver, etc.; Puerariae has the effect of lowering blood sugar.
- Salvia miltiorrhiza contains a large amount of diterpene quinone pigment, tanshinone, danshensu, diylaldehyde and other substances, which have the functions of promoting blood circulation and removing blood stasis, reducing blood viscosity, etc., and can well improve the blood viscosity of diabetic patients.
- Tianqi can dilate blood vessels, improve microcirculation disorders, lower blood lipids, scavenge free radicals, anti-inflammatory, antioxidant and other effects, improve fundus microcirculation and retinal ischemia
- Atractylodes Rhizoma can reduce hyperglycemia, hyperuricemia, hypertension and protect the myocardium.
- Cinnamon twig has anti-inflammatory, vasodilatory, antihypertensive, anticonvulsant, antiplatelet aggregation, and anticoagulant effects. Ginger has anti-inflammatory properties. It also has significant effects on the cardiovascular system and digestive system.
- Cornus has obvious immune regulation, hypoglycemic, anti-tumor, anti-aging and other effects.
- Cortex Phellodendri has various pharmacological effects, mainly including hypoglycemic, antibacterial, Anti-fungal, antitussive, antihypertensive, anti-trichomoniasis, anti-hepatitis, anti-ulcer and immunosuppressive effects.
- the prescription of the present invention can supplement Yin and Yang, promote blood circulation and remove blood stasis, resolve phlegm and reduce turbidity.
- this prescription is especially suitable for the treatment of diabetic nephropathy caused by deficiency of yin and yang and stasis caused by phlegm in the later stage of diabetes. It is effective, safe and reliable for patients with multiple complications of diabetes and chronic renal insufficiency.
- the formula consists of the following components: Pueraria 15g, Salvia 15g, Atractylodes 30g, Codonopsis 30g, Phellodendron 5g, Chuanxiong 15g, Tianqi 10g, Cinnamon 10g, Xianlingpi 15g, Cistanche 30g, Cornus 15g, Ginger 10g, Atractylodes 15g . Add water and cook to a bowl.
- Embodiment 2 (decoction)
- the formula consists of the following components: 14g Pueraria Root, 14g Salvia miltiorrhiza, 28g Atractylodes Rhizoma, 28g Codonopsis Radix, 4g Phellodendri, 14g Chuanxiong, 9g Panax Radix, 9g Guizhi, 14g Xianlingpi, 28g Cistanche, 14g Cornel, 9g Ginger, 14g Atractylodes . Add water and cook to a bowl.
- Embodiment 3 (decoction)
- Each dose of the formula is composed of the following components: 16g of Pueraria Root, 16g of Salvia miltiorrhiza, 32g of Atractylodes Rhizoma, 32g of Codonopsis Radix, 6g of Treats, 16g of Rhizoma Chuanxiong, 11g of Panax Radix, 11g of Cinnamon Branch, 16g of Xianlingpi, 32g of Cistanche, 16g of Cornus, 11g of Dried Ginger, Atractylodes 16g. Add water and cook to a bowl.
- the formula consists of the following components: 15g Pueraria lobata, 16g Salvia miltiorrhiza, 30g Atractylodes Rhizoma, 28g Codonopsis Radix, 6g Cortex Phellodendri, 14g Chuanxiong, 11g Tianqi, 9g Guizhi, 14g Lingpi, 30g Cistanche, 16g Cornel, 9g Ginger, 14g Atractylodes . Add water and cook to a bowl.
- the formula is composed of the following components: 18 parts of Pueraria lobata, 18 parts of Salvia miltiorrhiza, 35 parts of Atractylodes Rhizoma, 35 parts of Codonopsis Radix, 6 parts of Treats, 18 parts of Chuanxiong, 12 parts of Tianqi, 12 parts of Guizhi, 18 parts of Xianlingpi 35 parts of Cistanche, 18 parts of dogwood, 12 parts of dried ginger, and 18 parts of Atractylodes. . Extract with water twice, add 8-10 times of water each time, decoct for 1-1.5 hours, combine the water extracts, concentrate and dry to obtain dry extract.
- Example 5 Take 20 g of the dry extract obtained in Example 5 and grind it into fine powder, according to the capsule manufacturing process, add medicinal starch and micropowder silica gel, mix, sieve, and put into capsules to make 100 capsules to obtain capsules. The content of each capsule weighs 0.2g.
- the observation group included 18 males and 20 females, aged 60-75 years, average age (62.17 ⁇ 7.03) years, diabetes duration 8-21 years, mean duration (10.78 ⁇ 2.80) years, complications: 4 cases with gastroparesis , 2 cases with diabetic foot, 18 cases with peripheral neuropathy, 27 cases with retinopathy. There was no significant difference in general data between the two groups (P>0.05), which was comparable.
- TCM Syndrome Differentiation Criteria Dry mouth and throat, vexation and heat in the five hearts, pale complexion, mental fatigue, aversion to cold and cold limbs, swelling of the face and limbs, frequent urination, increased nocturia, turbidity as fat as ointment, and even drinking a fen yi, complexion Mucuna black, sore waist and knees, fullness in the abdomen and abdomen, poor appetite, impotence, diarrhea, pale tongue, fat body, white and dry coating, thin and weak pulse.
- Exclusion criteria (1) Exclude hospitalized patients with myocarditis, pericardial disease, other organic heart disease, electrolyte imbalance and other heart diseases; (2) Patients with severe cardiovascular and cerebrovascular and liver damage, or recent diabetic ketosis , hyperosmotic coma; (3) pregnancy, allergies, etc. who are not suitable for this treatment plan; (4) those who are older than 75 years old; (5) major changes in lifestyle during data collection, which may affect the results of the study Analyzed patients; (6) non-cooperators.
- Both groups were given comprehensive diabetes treatment, namely health education, diet management, exercise management, blood glucose monitoring and management, etc., and targeted interventions were given to those with comorbidities.
- the control group was additionally treated with Kaibotong (National Medicine Zhunzi H31022986, Shanghai Squibb Pharmaceuticals), orally, 12.5 mg/time, 2-3 times/d.
- the observation group was additionally treated with the Jianpi Tongyang formula of Example 1 of the present invention, decocted in water, 1 dose a day, decocted into 400 mL, 200 mL each time, warmed twice in the morning and evening, and the treatment results were counted after 2 months of treatment.
- Diabetes belongs to the category of "diabetes” in traditional Chinese medicine, and ancient traditional Chinese medicine mostly treats it from “dryness and heat due to yin deficiency”.
- the current clinical findings have changed in terms of etiology, pathogenesis and pathogenesis, clinical manifestations, and even treatment methods.
- Clinical practice shows that Jianpi Tongyang Recipe in the treatment of yin and yang deficiency with phlegm and blood stasis type diabetes not only has an exact hypoglycemic effect and is safe to use, but also has advantages over western medicine in reducing urinary protein and alleviating symptoms caused by diabetes.
- the selected 60 patients were randomly divided into 2 groups according to the ratio of 1:1, namely the traditional Chinese medicine group and the control group.
- the gender, age and other general data of the two groups were compared, and SPSS software was used to determine whether they were comparable (no significant difference P>0.05).
- CRF ulcerative colitis .
- 1 renal function compensation stage creatinine clearance (CCr) 50 ⁇ 80mL/min, serum creatinine (SCr) 133 ⁇ 177umol/L
- 2Renal decompensation stage CCr 20 ⁇ 50mL/min
- SCr 186 ⁇ 442umol/L 3 Renal failure stage: CCr 10 ⁇ 20mL/min, SCr 451 ⁇ 707umol/L
- 4 Uremia stage CCr ⁇ 10mL/ min, SCr>707umo1/L.
- 1 to 3 are the early and middle stages.
- TCM syndrome differentiation standard TCM syndrome differentiation is yin and yang deficiency with blood stasis and phlegm syndrome.
- Main symptoms chills and cold extremities, fatigue, shortness of breath, sluggishness, lack of appetite, soreness and weakness of the waist and knees.
- Secondary symptoms cold pain in the waist, abdominal distention, loose stools, clear and long nocturnal urination, pale tongue with tooth marks, and weak pulse.
- the control group was given a high-quality low-protein diet.
- the protein intake is determined according to the creatinine clearance rate. If the dietary protein intake is insufficient, an appropriate amount of essential amino acids can be given (oral or intravenous drip). Symptomatic treatment of anti-infection, correction of acidosis, antihypertensive, correction of electrolyte imbalance, etc. was given.
- the Chinese medicine group was given the Jianpi Tongyang formula of Example 1, decocted in water, 1 dose per day, decocted into 400mL, 200mL each time, warmed twice in the morning and evening, 4 weeks as a course of treatment, 2 Statistical treatment results after a course of treatment.
- Chronic renal insufficiency belongs to the categories of "guange”, “consumption”, “edema” and “low back pain” in traditional Chinese medicine.
- the pathogenesis of this disease is complex, with both the deficiency of righteousness and the inner connotation of evil.
- Most Chinese medicine practitioners believe that the basic pathogenesis of this disease is deficiency of yin and yang of the spleen and kidney, and blood stasis, dampness and turbidity run through the entire course of the disease.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Disclosed are a traditional Chinese medicine composition for invigorating the spleen and activating yang, and the use thereof. The composition is composed of the following ingredients in parts by weight: 12-18 parts of Puerariae lobatae radix, 12-18 parts of Salviae miltiorrhizae radix et rhizoma, 25-35 parts of Atractylodis macrocephalae rhizoma, 25-35 parts of Codonopsis radix, 4-6 parts of Phellodendri chinensis cortex, 12-18 parts of Chuanxiong rhizoma, 8-12 parts of Panax notoginseng, 8-12 parts of Cinnamomi ramulus, 12-18 parts of Epimedii folium, 25-35 parts of Cistanche deserticola, 12-18 parts of Corni fructus, 8-12 parts of Zingiberis rhizoma and 12-18 parts of Atractylodis rhizoma. The composition is used for treating diabetes, diabetic nephropathy and chronic renal disease caused by a deficiency of yin and yang, blood stasis and sputum. The composition has obvious curative effects on the symptoms of a patient, such as xerostomia, polydipsia, fatigue, asthenia, abdominal distention, a fear of cold, cold limbs, darkish complexion, soreness and weakness of the waist and knees, limb paralysis, blurred vision, frequent micturition, increased nocturia, cloudy or oily urine, impotence, facial edema or limb edema, morning diarrhea, a pale and plump tongue, a white and dry tongue coating, and a deep, thready and forceless pulse.
Description
本发明涉及中药组方领域,特别是一种健脾通阳中药组合物。The invention relates to the field of traditional Chinese medicine formulations, in particular to a traditional Chinese medicine composition for strengthening the spleen and activating yang.
糖尿病是临床常见病、多发病,2010年宁光教授团队在中国18岁以上的人群中调查的糖尿病和糖尿病前期的患病率分别达到11.6%和50.1%。我国糖尿病患病率逐年增加,尤其是近几年患病率骤升,发展趋势不容乐观,且发病情况有所变化,有流行病学资料显示我国糖尿病肥胖者占80%以上。Diabetes is a common and frequently-occurring disease in clinical practice. In 2010, Prof. Ning Guang's team surveyed the prevalence of diabetes and prediabetes among people over 18 years old in China, reaching 11.6% and 50.1%, respectively. The prevalence of diabetes in my country is increasing year by year, especially in recent years, the prevalence rate has risen sharply, the development trend is not optimistic, and the incidence has changed. Epidemiological data show that more than 80% of diabetics are obese in my country.
糖尿病,现代中医多归属于中医学“消渴”范畴。消渴病相关的论述最早见于《内经》,有“消瘅”,“三消”,“膈消”“消中”等病名。《说文解字》中的解释:“消,尽也”,为“消瘦、消散、消耗”的意思。“渴,欲也”,为“口干欲饮”的意思。从字面上的概念看,此病名是对存在类似症状病人的归纳。古代医家论述消渴病的病机时形成了多种学说,历代医家对该病病机都有丰富和发展,形成了包括阴虚燥热说、三消说、肝郁气滞说、瘀血致消说等病机认识。Diabetes, modern Chinese medicine mostly belongs to the category of "diabetes" in Chinese medicine. The related discussion of diabetes mellitus was first seen in the "Nei Jing", including "xiaoheng", "three eliminations", "diaphragm elimination", "xiaozhong" and other disease names. The explanation in "Shuowen Jiezi": "to disappear, to exhaust" means "to lose weight, dissipate, and consume". "Thirsty and desire" means "dry mouth and desire to drink". Literally, this disease name is a generalization of patients with similar symptoms. Ancient physicians formed various theories when discussing the pathogenesis of diabetes mellitus. Physicians of past dynasties have enriched and developed the pathogenesis of the disease, including the theory of yin deficiency and dryness, the theory of three eliminations, the theory of liver stagnation and qi stagnation, and the theory of blood stasis. Dispelling and other pathogenesis understanding.
目前多认为,病变脏腑多责之肺胃肾,基本病机为“阴虚为本,燥热为标”,治疗则重在“养阴清热”。At present, it is generally believed that the basic pathogenesis of the lung, stomach and kidney with multiple responsibilities of the diseased viscera is "Yin deficiency is the foundation, dryness and heat are the standard", and the treatment focuses on "nourishing yin and clearing heat".
然而,现今临床发现不论是病因病机与发病,还是临床表现,乃至治疗方法,都与古代不同。申请人在长期临床实践中发现,现代糖尿病人饮水连连却不解其渴,所饮之水不能化生津液而小便频频;消渴病人多食而易饥,且肌肤不荣,所食水谷不养四肢而形体消瘦;现代之消渴病人肥胖者居多,肥人多痰,痰湿素盛,湿盛伤脾,典型“阴虚燥热型消渴”的病人已经少见,养阴则助湿碍脾,清热则伤脾阳而痰湿更甚。所以,不管“阴虚”还是“燥热”,都只是消渴病的“标”,只看到消渴的症状,而忽视疾病的根本。However, today's clinical findings are different from those in ancient times in terms of etiology, pathogenesis and pathogenesis, clinical manifestations, and even treatment methods. In the long-term clinical practice, the applicant found that modern diabetics drink water again and again but do not quench their thirst. The water they drink cannot be transformed into body fluid and urinate frequently; Nourishing the limbs and the body is thin; modern diabetes patients are mostly obese, obese people have more phlegm, phlegm-dampness is full, dampness damages the spleen, the typical "Yin deficiency and dry-heat diabetes" patients are rare, and nourishing yin helps dampness. Spleen, clearing heat will damage spleen-yang and phlegm-dampness will be worse. Therefore, no matter "yin deficiency" or "dry heat", they are only the "marks" of diabetes, and only the symptoms of diabetes are seen, while the root of the disease is ignored.
现代糖尿病病机已从“阴虚燥热”,演变为“脾胃虚弱、清阳不升、湿浊下注、相火郁闭”,脾胃元气不足,来自下焦之湿浊阴火乘机上乘,消耗人体的气血津液,气血津液施布障碍,不循常道而致“消渴”,应以“补脾胃、升清阳、泻湿浊、降阴火”治之。The pathogenesis of modern diabetes has evolved from "dry heat due to yin deficiency" to "weak spleen and stomach, lack of clear yang, dampness and turbidity, and stagnation of fire." The qi, blood, and body fluids of qi, blood and body fluids are blocked, and "diabetes" is caused by not following the normal path. It should be treated by "invigorating the spleen and stomach, raising the yang, removing dampness and turbidity, and reducing yin fire".
现代糖尿病人后期多表现为阴阳俱虚,以脾肾阴阳两虚为主,兼以痰、浊、瘀实邪。很多糖尿病后期多累及肾,而早期糖尿病肾病患者出现微量白蛋白尿,这与肾小球受损,肾小球系膜增生和肾小球基底膜增厚等有关。ACEI降低蛋白尿的作用已成为共识,作为血管紧张素转换酶抑制剂的代表药物开博通可起到扩张血管、延缓病情进展的作用,但是无法逆转病变,临床疗效十分有限。中医药疗法在糖尿病肾病临床治疗过程中的优越性日益显现。然而,关于治疗糖尿病后期,尤其是并发糖尿病肾病 的中成药较少,有的着重于益气养阴,活血通络,如渴络欣胶囊;有的着重于益肾固精,生津止渴,如金诃降糖胶囊等等,暂无与本验方脾肾同调、阴阳双补、活血祛瘀、化痰降浊功效相近的相关研究,市场暂无此类品种供应。In the later stage of modern diabetes, both yin and yang are mostly manifested as deficiency of both yin and yang. Many patients with late stage diabetes involve the kidneys, and patients with early stage diabetic nephropathy develop microalbuminuria, which is related to glomerular damage, mesangial hyperplasia and glomerular basement membrane thickening. The role of ACEI in reducing proteinuria has become a consensus. As a representative drug of angiotensin-converting enzyme inhibitor, Kaibotong can dilate blood vessels and delay the progression of the disease, but it cannot reverse the disease, and its clinical efficacy is very limited. The superiority of traditional Chinese medicine therapy in the clinical treatment of diabetic nephropathy is increasingly apparent. However, there are few Chinese patent medicines for the treatment of late stage diabetes, especially complicated diabetic nephropathy. Some focus on nourishing qi and nourishing yin, promoting blood circulation and dredging collaterals, such as Keluoxin capsule; For example, Jinhe Jiangtang Capsules, etc., there is no relevant research on the effects of spleen-kidney synchronization, yin and yang supplementation, blood circulation and blood stasis, phlegm and turbidity reduction, and there is no such variety in the market.
发明内容SUMMARY OF THE INVENTION
为解决现有技术的问题,本发明的目的是提供一种健脾通阳中药组合物,其疗效确切,具有脾肾同调、阴阳双补、活血祛瘀、化痰降浊的功效,攻补兼施,配伍精当,理法特色明显,治疗糖尿病后期,阴阳两虚,虚实夹杂,肺脾肾三脏虚损,夹痰、浊、瘀等实证所致糖尿病及糖尿病肾病、慢性肾功能不全患者安全有效。In order to solve the problems of the prior art, the object of the present invention is to provide a traditional Chinese medicine composition for strengthening spleen and yang yang, which has exact curative effect, and has the effects of synchronizing the spleen and kidney, tonifying yin and yang, promoting blood circulation and removing blood stasis, resolving phlegm and reducing turbidity. It can be used concurrently, well-matched, and the characteristics of the principles and methods are obvious. It is safe for patients with diabetes, diabetic nephropathy, and chronic renal insufficiency caused by evidences such as late stage diabetes, deficiency of yin and yang, mixed deficiency and excess, deficiency of lung, spleen, and kidney, phlegm, turbidity, blood stasis, etc. efficient.
本发明的另一个目的是将上述健脾通阳中药组合物应用于制备治疗糖尿病及糖尿病肾病、慢性肾功能不全的药物上。Another object of the present invention is to apply the above-mentioned Chinese medicinal composition for strengthening the spleen and clearing the yang in the preparation of medicines for the treatment of diabetes, diabetic nephropathy and chronic renal insufficiency.
发明的目的是这样实现的:一种健脾通阳中药组合物,其特征在于:按重量份数计算,配方由以下组分组成:葛根12-18份、丹参12-18份、白术25-35份、党参25-35份、黄柏4-6份、川芎12-18份、田七8-12份、桂枝8-12份、仙灵脾12-18份、肉苁蓉25-35份、山茱萸12-18份、干姜8-12份、苍术12-18份。The object of the invention is achieved in this way: a kind of traditional Chinese medicine composition for strengthening the spleen and activating yang, is characterized in that: by weight, the formula is made up of the following components: 12-18 parts of pueraria, 12-18 parts of Salvia miltiorrhiza, 25- 35 parts, Codonopsis 25-35 parts, Treats 4-6 parts, Chuanxiong 12-18 parts, Tian Qi 8-12 parts, Guizhi 8-12 parts, Xianlingpi 12-18 parts, Cistanche deserticola 25-35 parts, Dogwood 12-18 servings, 8-12 servings of dried ginger, and 12-18 servings of Atractylodes.
优选的,按重量份数计算,配方由以下组分组成:葛根14-16份、丹参14-16份、白术28-32份、党参28-32份、黄柏4-6份、川芎14-16份、田七9-11份、桂枝9-11份、仙灵脾14-16份、肉苁蓉28-32份、山茱萸14-16份、干姜9-11份、苍术14-16份。Preferably, calculated in parts by weight, the formula is composed of the following components: 14-16 parts of Pueraria, 14-16 parts of Salvia, 28-32 parts of Atractylodes, 28-32 parts of Codonopsis, 4-6 parts of Treats, 14-16 parts of Chuanxiong parts, 9-11 parts of Tianqi, 9-11 parts of Guizhi, 14-16 parts of Xianlingpi, 28-32 parts of Cistanche deserticola, 14-16 parts of dogwood, 9-11 parts of dried ginger, and 14-16 parts of Atractylodes.
最优选的,按重量份数计算,配方由以下组分组成:葛根15份、丹参15份、白术30份、党参30份、黄柏5份、川芎15份、田七10份、桂枝10份、仙灵脾15份、肉苁蓉30份、山茱萸15份、干姜10份、苍术15份。Most preferably, calculated in parts by weight, the formula is made up of the following components: 15 parts of Pueraria lobata, 15 parts of Salvia miltiorrhiza, 30 parts of Atractylodes Rhizoma, 30 parts of Codonopsis Radix, 5 parts of Treats, 15 parts of Chuanxiong, 10 parts of Tianqi, 10 parts of Guizhi , 15 copies of Xianlingpi, 30 copies of Cistanche, 15 copies of dogwood, 10 copies of dried ginger, and 15 copies of Atractylodes.
所述健脾通阳中药组合物在制备治疗糖尿病、糖尿病肾病、慢性肾功能不全的药物的应用。The application of the traditional Chinese medicine composition for strengthening spleen and activating yang in preparing medicines for treating diabetes, diabetic nephropathy and chronic renal insufficiency.
所述的药物为汤剂、颗粒剂、片剂、胶囊剂、口服液或丸剂。The medicine is decoction, granule, tablet, capsule, oral liquid or pill.
所述的药物为以所述健脾通阳中药组合物配方中组分的提取物为有效成分,添加药用辅料制得的制剂。The medicine is a preparation prepared by using the extract of the components in the formula of the Chinese medicine composition for strengthening the spleen and removing yang as the active ingredient, and adding medicinal excipients.
所述的提取物为水提取物。The extract is a water extract.
所述的糖尿病是糖尿病后期。Said diabetes is the late stage of diabetes.
所述的糖尿病、糖尿病肾病、慢性肾功能不全是阴阳两虚夹瘀、痰型的糖尿病、糖尿病肾病、慢性肾功能不全。The diabetes, diabetic nephropathy and chronic renal insufficiency are phlegm-type diabetes, diabetic nephropathy and chronic renal insufficiency.
本发明是“从脾胃论治糖尿病”的组方,具有阴阳双补、活血祛瘀、化痰降浊之功,用于阴阳两虚夹瘀、痰所致的消渴病,症见口干多饮、神疲乏力、脘腹胀满、畏寒肢冷、面色黧黑、腰膝酸软、 肢体麻痹、视物模糊、小便频数、夜尿增多浑浊如脂如膏、阳痿、面目浮肿或肢体浮肿、五更泄泻,舌淡体胖苔白而干,脉沉细无力等;糖尿病及糖尿病肾病、慢性肾功能不全等见上述证候者服用后均有明显疗效。The present invention is a formula for "treatment of diabetes from the spleen and stomach". Polydipsia, mental fatigue, fullness of the abdomen and abdomen, chills, cold limbs, dark complexion, weak waist and knees, limb paralysis, blurred vision, frequent urination, increased nocturnal urination, turbidity, impotence, swollen face or swollen limbs, Diarrhea, pale tongue, fat body, white and dry coating, thin and weak pulse, etc. Diabetes, diabetic nephropathy, chronic renal insufficiency, etc. have obvious curative effect after taking the medicine.
发明是一种健脾通阳中药组合物,其特征在于:按重量份数计算,配方由以下组分组成:葛根12-18份、丹参12-18份、白术25-35份、党参25-35份、黄柏4-6份、川芎12-18份、田七8-12份、桂枝8-12份、仙灵脾12-18份、肉苁蓉25-35份、山茱萸12-18份、干姜8-12份、苍术12-18份。优选的,按重量份数计算,配方由以下组分组成:葛根14-16份、丹参14-16份、白术28-32份、党参28-32份、黄柏4-6份、川芎14-16份、田七9-11份、桂枝9-11份、仙灵脾14-16份、肉苁蓉28-32份、山茱萸14-16份、干姜9-11份、苍术14-16份。最优选的,按重量份数计算,配方由以下组分组成:葛根15份、丹参15份、白术30份、党参30份、黄柏5份、川芎15份、田七10份、桂枝10份、仙灵脾15份、肉苁蓉30份、山茱萸15份、干姜10份、苍术15份。The invention is a traditional Chinese medicine composition for strengthening the spleen and activating yang, which is characterized in that: calculated in parts by weight, the formula is composed of the following components: 12-18 parts of Pueraria lobata, 12-18 parts of Salvia miltiorrhiza, 25-35 parts of Atractylodes Rhizoma, 25-35 parts of Codonopsis Radix. 35 parts, 4-6 parts of Cork, 12-18 parts of Chuanxiong, 8-12 parts of Tianqi, 8-12 parts of Guizhi, 12-18 parts of Xianlingpi, 25-35 parts of Cistanche, 12-18 parts of dogwood, dried Ginger 8-12 parts, Atractylodes 12-18 parts. Preferably, calculated in parts by weight, the formula is composed of the following components: 14-16 parts of Pueraria, 14-16 parts of Salvia, 28-32 parts of Atractylodes, 28-32 parts of Codonopsis, 4-6 parts of Treats, 14-16 parts of Chuanxiong parts, 9-11 parts of Tianqi, 9-11 parts of Guizhi, 14-16 parts of Xianlingpi, 28-32 parts of Cistanche deserticola, 14-16 parts of dogwood, 9-11 parts of dried ginger, and 14-16 parts of Atractylodes. Most preferably, calculated in parts by weight, the formula is made up of the following components: 15 parts of Pueraria lobata, 15 parts of Salvia miltiorrhiza, 30 parts of Atractylodes Rhizoma, 30 parts of Codonopsis Radix, 5 parts of Treats, 15 parts of Chuanxiong, 10 parts of Tianqi, 10 parts of Guizhi , 15 copies of Xianlingpi, 30 copies of Cistanche, 15 copies of dogwood, 10 copies of dried ginger, and 15 copies of Atractylodes.
所述健脾通阳中药组合物在制备治疗糖尿病、糖尿病肾病、慢性肾功能不全的药物的应用,尤其是阴阳两虚夹瘀、痰型的糖尿病、糖尿病肾病、慢性肾功能不全。优选的,所述的糖尿病为糖尿病后期及其并发症。所述的药物可以为汤剂、颗粒剂、片剂、胶囊剂、口服液或丸剂等口服剂型。所述的药物为以所述健脾通阳中药组合物配方中组分的提取物为有效成分,添加相应剂型的药用辅料按已有通用工艺制得的相应制剂。优选的,所述的提取物为水提取物。The application of the Chinese medicine composition for strengthening spleen and activating yang in the preparation of medicines for treating diabetes, diabetic nephropathy and chronic renal insufficiency, especially yin and yang deficiency with blood stasis, phlegm-type diabetes, diabetic nephropathy and chronic renal insufficiency. Preferably, the diabetes is the late stage of diabetes and its complications. The medicament can be in oral dosage forms such as decoction, granule, tablet, capsule, oral liquid or pill. The medicine is a corresponding preparation prepared by using the extracts of the components in the formula of the Chinese medicine composition for strengthening the spleen and removing the yang as active ingredients, and adding pharmaceutical excipients of corresponding dosage forms according to the existing general process. Preferably, the extract is a water extract.
本发明组方来自发明人“从脾胃论治糖尿病”理论体系,认为糖尿病病机为:“脾胃失调,物不归化,精微不运,脏腑失养”,故治疗以调和脾胃,攻补兼施为核心。糖尿病早期多表现为脾虚郁热,脉络瘀滞,后期多表现为阴阳俱虚,以脾肾阴阳两虚为主,兼以痰、浊、瘀实邪。The formula of the present invention comes from the theoretical system of the inventor's "Treatment of Diabetes from the Spleen and Stomach", and it is believed that the pathogenesis of diabetes is: "The spleen and stomach are out of balance, the things are not naturalized, the subtleties are not transported, and the organs are out of nourishment", so the treatment is to reconcile the spleen and stomach, attack and supplement both Shi is the core. In the early stage of diabetes, spleen deficiency is often manifested as stagnation and heat, and blood stasis is present. In the later stage, both yin and yang deficiency are mostly manifested.
消渴病症状以消耗多食,口干多饮为主,饮食的代谢与运化,与脾胃关系最为密切。那么,水饮进入人体如何代谢的呢?《素问·经脉别论》云:“饮入于胃,游溢精气,上输于脾,脾气散精,上归于肺,通调水道,下输膀胱。水精四布,五经并行”。正常情况下,饮食水谷进入人体,经胃之腐熟,化生精微物质,经脾之运化,将精微物质散布全身,支持全身功能活动。当饮食失常,脾胃受损时,就要发病。可见,早在《内经》时期就明确提出了消渴发病或因过食肥甘厚味,内伤脾胃,或因胃中积热,根本在于“脾胃”。The symptoms of diabetes mellitus are mainly consumption of more food, dry mouth and more drinking. The metabolism, transportation and transformation of diet are most closely related to the spleen and stomach. So, how is water metabolized into the human body? "Plain Questions: The Differentiation of Meridians" says: "Drinking enters the stomach, escaping the essence and qi, and transporting it upward to the spleen, dispersing the spleen, returning to the lungs, regulating the water channels, and transporting the bladder downward. Under normal circumstances, food and water grains enter the human body, decompose through the stomach, metamorphose into the subtle substances, and transport and transform through the spleen to spread the subtle substances throughout the body to support the functional activities of the whole body. When the diet is disordered and the spleen and stomach are damaged, the disease will occur. It can be seen that as early as the "Neijing" period, it was clearly proposed that the onset of diabetes is either due to overeating fat, sweet and thick taste, internal injury to the spleen and stomach, or due to accumulation of heat in the stomach, which is fundamentally in the "spleen and stomach".
(一)脾胃失调,物不归化,日久则内生热、郁、湿、痰、浊、瘀。(1) The spleen and stomach are out of balance, and things are not naturalized. Over time, heat, stagnation, dampness, phlegm, turbidity, and blood stasis are generated.
饮食肥甘厚味,损伤脾胃,运化不及,体内的糟粕无法通过脾胃升清降浊作用排出,蕴积肠腑而生内热,煎灼津液,则燥邪、热邪内生,发为消渴病。Fatty, sweet and thick-flavored diet damages the spleen and stomach, and cannot be transported and transformed. Thirst.
消渴日久,肥甘厚味,膏粱之变,内伤脾胃,脾虚则痰湿内生,发为消渴。Diabetes the thirst for a long time, fat, sweet and thick taste, the change of the cream, the internal injury to the spleen and stomach, the spleen deficiency, the phlegm-dampness is endogenous, and the hair is diabetes.
情志抑郁、肝气不舒,瘀血郁久化热也会导致消渴的病机。Emotional depression, liver qi discomfort, stagnation of blood and heat for a long time will also lead to the pathogenesis of thirst.
(二)脾失健运,精微不运,脏腑失养,则气血亏虚,日久阴阳俱虚。(2) If the spleen fails to function properly, the subtleties are not transported, and the viscera fails to nourish, the qi and blood will be deficient, and both yin and yang will be deficient over time.
脾胃居中焦,运化水谷,为气机升降之枢纽,气血生化之来源。若脾失健运,则脾不能散精,精微上不能归于肺,下不能输于膀胱,则脏腑失养。中焦脾胃受损,血液生化无源,气血亏虚,正气不足,不只发为消渴,又可出现多种变证。血脉失养,经络不和,可见肢体麻痹之证;肝肾阴亏,不能上养耳目,可见视瞻昏渺、暴盲、耳聋等证;瘀阻络脉,正气亏虚,易感热毒而发疮疖、痈疽。The spleen and stomach are located in the middle coke, which transports and transforms water and valleys. If the spleen fails to function properly, the spleen cannot disperse the essence, the upper essence cannot be transferred to the lungs, and the lower essence cannot be transported to the bladder, and the viscera cannot be nourished. Damage to the spleen and stomach of the middle burner, passive blood biochemistry, deficiency of qi and blood, and lack of righteousness, not only cause diabetes, but also various syndromes. Dystrophy of blood vessels, disharmony of meridians and collaterals, showing signs of paralysis of limbs; deficiency of liver and kidney yin, inability to nourish ears and eyes, showing signs of dim vision, sudden blindness, deafness, etc. And sores and boils, carbuncle.
本发明结合大量临床实际,认为消渴临床常见虚实夹杂之证,且虚实夹杂贯穿消渴病整个病程。虚证以气虚、阴虚为主,一般而言,早期多表现为脾虚肺热、脾虚胃实、脾虚肝郁,中期脾肺两虚、心脾两虚、脾肾两虚,后期损及阴阳,而发展为阴阳两虚或脾虚络阻之证。兼证多为实证,以郁、热、湿、痰、浊、瘀为主,往往由多个邪气互相夹杂为病,或出现于消渴的整个病程,或在某个阶段较为突出。因此,调和脾胃,攻补兼施为核心治疗方法,补脾扶正是核心,在扶正的过程中,必需重视驱邪。Combined with a large number of clinical practice, the present invention believes that the syndrome of deficiency and excess is common in the clinical diagnosis of diabetes, and the combination of deficiency and excess runs through the entire course of diabetes. Deficiency syndrome is mainly qi deficiency and yin deficiency. Generally speaking, in the early stage, it is mostly manifested as spleen deficiency and lung heat, spleen deficiency and stomach deficiency, spleen deficiency and liver stagnation. , and develop into a syndrome of yin and yang deficiency or spleen deficiency and collateral obstruction. Concurrent syndromes are mostly evidence, mainly stagnation, heat, dampness, phlegm, turbidity, and blood stasis, often caused by multiple evil qi intermingled with each other, or appearing in the entire course of diabetes, or more prominent at a certain stage. Therefore, reconciling the spleen and stomach, attacking and nourishing as the core treatment method, and nourishing the spleen and strengthening the core are the core. In the process of strengthening the righteousness, attention must be paid to exorcising evil spirits.
现代糖尿病人后期多并发糖尿病肾病,表现为阴阳俱虚,以脾肾阴阳两虚为主,兼以痰、浊、瘀实邪,部分慢性肾功能不全患者也表现出同样的证候。针对这样的病情特点,以本发明中药组合物治疗,对糖尿病及糖尿病肾病、慢性肾功能不全疗效肯定、确切。方中白术健脾益气燥湿,党参补中益气,使中轴得运,共为君药;配伍仙灵脾、肉苁蓉温肾助阳,共为臣药;佐以葛根升清阳以通脾络,解热以生津止渴,丹参、川芎、田七以活血化瘀通脾络,苍术健脾燥湿,化痰辟浊,桂枝配伍干姜温经通络;山茱萸滋补肾阴,于温阳药中取“阳中求阴”,并用黄柏清热燥湿助脾以泻降阴火,引火归元共为使药。全方升降和合,共凑脾肾同调、阴阳双补、活血祛瘀、化痰降浊之功。Diabetic nephropathy is often complicated by modern diabetic patients in the later stage, which is characterized by deficiency of both yin and yang, mainly yin and yang deficiency of spleen and kidney, and pathogenic factors such as phlegm, turbidity and blood stasis. Some patients with chronic renal insufficiency also show the same syndrome. Aiming at the characteristics of such a disease, treating with the traditional Chinese medicine composition of the present invention has a certain and exact curative effect on diabetes, diabetic nephropathy and chronic renal insufficiency. In the prescription, Atractylodes Rhizoma invigorates the spleen and replenishes Qi and dries dampness, and Codonopsis pilosula tonifies the middle and invigorates Qi, so that the central axis can be transported, and they are the monarch medicine. It is combined with Xianlingpi and Cistanche to warm the kidney and help the yang, and they are the minister medicine. Unblocks the spleen and collaterals, relieves heat to produce body fluid and quenches thirst, Salvia miltiorrhiza, Chuanxiong and Tianqi promote blood circulation and remove blood stasis and clear the spleen and collaterals, Atractylodes japonica invigorates the spleen and removes dampness, resolves phlegm and removes turbidity. From the yang-warming medicine, "seeking yin in yang" is used, and Huangbai is used to clear heat and dry dampness to help the spleen to purify and reduce yin-fire. The whole formula ascends and descends and harmonizes together, combining the functions of spleen and kidney harmony, yin and yang supplementation, promoting blood circulation and removing blood stasis, resolving phlegm and reducing turbidity.
根据现代研究,此方中白术,具有促进受损植物神经功能的恢复,调整人体脏腑功能平衡和调节胃肠运动、降糖、利尿、增强抵抗力等作用,党参多糖能够降低四氧嘧啶致糖尿病小鼠的血糖,同时能在一定程度上改善胰岛素抵抗,提高机体胰岛素的敏感性;仙灵脾具有提高机体免疫功能、抗衰老、抗氧化、抗炎、降血糖、抗抑郁等多种药理作用,肉苁蓉具有抗氧化和抗衰老、神经保护、缺血再灌注、提高免疫力、保肝护肝等作用;葛根有降血糖作用,以葛根组方及其提取物的制剂已广泛用于糖尿病及其并发症的治疗,丹参含有大量的二萜醌色素、丹参酮、丹参素、二基醛等多种物质,具有活血化瘀、降低血液粘度等作用,能很好的改善糖尿病患者的血黏度状况,川芎具有镇静镇痛、抑制氧自由基释放等作用,田七能够扩张血管、改善微循环障碍、降血脂、清除自由基、抗炎、抗氧化等作用,改善眼底微循环及视网膜的缺血缺氧状态,苍术能降低高血糖、高血尿酸、高血压以及保护心肌,桂枝具有抗炎、扩张血管、降压、抗惊厥、抗血小板聚集、抗凝血等功效,干姜具有抗炎、抑菌等作用,并且对心血管系统及消化系统也有显著效用,山茱萸具有明显的免疫调节、降血糖、抗肿瘤、抗衰老 等作用,黄柏具有多方面药理作用,主要包括降糖、抗菌、抗真菌、镇咳、降压、抗滴虫、抗肝炎、抗溃疡以及免疫抑制作用等。According to modern research, Atractylodes macrocephala in this recipe can promote the recovery of damaged autonomic nerve function, adjust the balance of human viscera functions, regulate gastrointestinal motility, lower blood sugar, diuresis, and enhance resistance. Codonopsis polysaccharide can reduce alloxan-induced diabetes. At the same time, it can improve insulin resistance and insulin sensitivity of the body to a certain extent; Xianlingpi has various pharmacological effects such as improving immune function, anti-aging, anti-oxidation, anti-inflammatory, hypoglycemic, and anti-depression. , Cistanche deserticola has anti-oxidation and anti-aging, neuroprotection, ischemia-reperfusion, improving immunity, protecting the liver and protecting the liver, etc.; Puerariae has the effect of lowering blood sugar. For the treatment of its complications, Salvia miltiorrhiza contains a large amount of diterpene quinone pigment, tanshinone, danshensu, diylaldehyde and other substances, which have the functions of promoting blood circulation and removing blood stasis, reducing blood viscosity, etc., and can well improve the blood viscosity of diabetic patients. , Chuanxiong has sedative and analgesic, inhibiting the release of oxygen free radicals, etc., Tianqi can dilate blood vessels, improve microcirculation disorders, lower blood lipids, scavenge free radicals, anti-inflammatory, antioxidant and other effects, improve fundus microcirculation and retinal ischemia In hypoxic state, Atractylodes Rhizoma can reduce hyperglycemia, hyperuricemia, hypertension and protect the myocardium. Cinnamon twig has anti-inflammatory, vasodilatory, antihypertensive, anticonvulsant, antiplatelet aggregation, and anticoagulant effects. Ginger has anti-inflammatory properties. It also has significant effects on the cardiovascular system and digestive system. Cornus has obvious immune regulation, hypoglycemic, anti-tumor, anti-aging and other effects. Cortex Phellodendri has various pharmacological effects, mainly including hypoglycemic, antibacterial, Anti-fungal, antitussive, antihypertensive, anti-trichomoniasis, anti-hepatitis, anti-ulcer and immunosuppressive effects.
因此,本发明方阴阳双补、活血祛瘀、化痰降浊,通过下述临床研究的数据,证明本方尤其适用于治疗糖尿病后期表现为阴阳两虚夹瘀、痰所致的糖尿病肾病及糖尿病多发并发症、慢性肾功能不全患者,疗效确切、安全可靠。Therefore, the prescription of the present invention can supplement Yin and Yang, promote blood circulation and remove blood stasis, resolve phlegm and reduce turbidity. Through the following clinical research data, it is proved that this prescription is especially suitable for the treatment of diabetic nephropathy caused by deficiency of yin and yang and stasis caused by phlegm in the later stage of diabetes. It is effective, safe and reliable for patients with multiple complications of diabetes and chronic renal insufficiency.
实施例1(汤剂)Example 1 (decoction)
配方由以下组分组成:葛根15g、丹参15g、白术30g、党参30g、黄柏5g、川芎15g、田七10g、桂枝10g、仙灵脾15g、肉苁蓉30g、山茱萸15g、干姜10g、苍术15g。加水煎煮至一碗服用。The formula consists of the following components: Pueraria 15g, Salvia 15g, Atractylodes 30g, Codonopsis 30g, Phellodendron 5g, Chuanxiong 15g, Tianqi 10g, Cinnamon 10g, Xianlingpi 15g, Cistanche 30g, Cornus 15g, Ginger 10g, Atractylodes 15g . Add water and cook to a bowl.
实施例2(汤剂)Embodiment 2 (decoction)
配方由以下组分组成:葛根14g、丹参14g、白术28g、党参28g、黄柏4g、川芎14g、田七9g、桂枝9g、仙灵脾14g、肉苁蓉28g、山茱萸14g、干姜9g、苍术14g。加水煎煮至一碗服用。The formula consists of the following components: 14g Pueraria Root, 14g Salvia miltiorrhiza, 28g Atractylodes Rhizoma, 28g Codonopsis Radix, 4g Phellodendri, 14g Chuanxiong, 9g Panax Radix, 9g Guizhi, 14g Xianlingpi, 28g Cistanche, 14g Cornel, 9g Ginger, 14g Atractylodes . Add water and cook to a bowl.
实施例3(汤剂)Embodiment 3 (decoction)
配方每剂由以下组分组成:葛根16g、丹参16g、白术32g、党参32g、黄柏6g、川芎16g、田七11g、桂枝11g、仙灵脾16g、肉苁蓉32g、山茱萸16g、干姜11g、苍术16g。加水煎煮至一碗服用。Each dose of the formula is composed of the following components: 16g of Pueraria Root, 16g of Salvia miltiorrhiza, 32g of Atractylodes Rhizoma, 32g of Codonopsis Radix, 6g of Treats, 16g of Rhizoma Chuanxiong, 11g of Panax Radix, 11g of Cinnamon Branch, 16g of Xianlingpi, 32g of Cistanche, 16g of Cornus, 11g of Dried Ginger, Atractylodes 16g. Add water and cook to a bowl.
实施例4(汤剂)Example 4 (decoction)
配方由以下组分组成:葛根15g、丹参16g、白术30g、党参28g、黄柏6g、川芎14g、田七11g、桂枝9g、仙灵脾14g、肉苁蓉30g、山茱萸16g、干姜9g、苍术14g。加水煎煮至一碗服用。The formula consists of the following components: 15g Pueraria lobata, 16g Salvia miltiorrhiza, 30g Atractylodes Rhizoma, 28g Codonopsis Radix, 6g Cortex Phellodendri, 14g Chuanxiong, 11g Tianqi, 9g Guizhi, 14g Lingpi, 30g Cistanche, 16g Cornel, 9g Ginger, 14g Atractylodes . Add water and cook to a bowl.
实施例5(片剂)Example 5 (tablet)
按重量份计算,配方由以下组分组成:葛根18份、丹参18份、白术35份、党参35份、黄柏6份、川芎18份、田七12份、桂枝12份、仙灵脾18份、肉苁蓉35份、山茱萸18份、干姜12份、苍术18份。。水提两次,每次加8-10倍的水,煎煮1-1.5小时,合并水提液,浓缩干燥,得到干浸膏。Calculated by weight, the formula is composed of the following components: 18 parts of Pueraria lobata, 18 parts of Salvia miltiorrhiza, 35 parts of Atractylodes Rhizoma, 35 parts of Codonopsis Radix, 6 parts of Treats, 18 parts of Chuanxiong, 12 parts of Tianqi, 12 parts of Guizhi, 18 parts of Xianlingpi 35 parts of Cistanche, 18 parts of dogwood, 12 parts of dried ginger, and 18 parts of Atractylodes. . Extract with water twice, add 8-10 times of water each time, decoct for 1-1.5 hours, combine the water extracts, concentrate and dry to obtain dry extract.
取干浸膏20g研磨成细粉,按片剂制造工艺,加入药用淀粉和微粉硅胶,混合、制粒、干燥、整粒,然后加入硬脂酸镁,混匀,压制成100片,即得片剂。每片重0.3g。Take 20g of dry extract and grind it into fine powder, according to the tablet manufacturing process, add medicinal starch and micropowder silica gel, mix, granulate, dry and granulate, then add magnesium stearate, mix well, and press into 100 tablets, namely Get tablets. Each tablet weighs 0.3g.
实施例6(胶囊剂)Example 6 (capsule)
取实施例5制得的干浸膏20g研磨成细粉,按胶囊剂制造工艺,加入药用淀粉和微粉硅胶,混合、过筛、装入胶囊中,制成100粒,即得胶囊。每粒内容物重重0.2g。Take 20 g of the dry extract obtained in Example 5 and grind it into fine powder, according to the capsule manufacturing process, add medicinal starch and micropowder silica gel, mix, sieve, and put into capsules to make 100 capsules to obtain capsules. The content of each capsule weighs 0.2g.
临床对比实验Clinical comparative experiment
为了客观评价本发明中药组合物的临床有效性与安全性,按照中药新药临床研究指南的要求,对该药进行临床研究。以下研究均经汕头市中医院伦理委员会批准,患者均对本研究知情同意。In order to objectively evaluate the clinical effectiveness and safety of the traditional Chinese medicine composition of the present invention, according to the requirements of the clinical research guidelines for new traditional Chinese medicines, clinical research is carried out on the medicine. The following studies were approved by the Ethics Committee of Shantou Hospital of Traditional Chinese Medicine, and all patients gave informed consent to this study.
一、治疗糖尿病及糖尿病肾病的临床研究1. Clinical research on the treatment of diabetes and diabetic nephropathy
1临床资料1Clinical data
1.1一般资料 选取2016年1月至2018年2月汕头市中医医院糖尿病科门诊及住院治疗的64例阴阳两虚夹瘀、痰型2型糖尿病肾病患者,随机将其分为对照组和观察组,每组32例。对照组男15例,女17例;年龄61~72岁,平均年龄(66.89±5.13)岁,糖尿病病程10~20年,平均病程(10.26±2.75)年,并发症(部分患者合并2个或2个以上并发症),3例合并胃轻瘫,3例合并糖尿病足,19例合并周围神经病变,28例合并视网膜病变。观察组男性18例、女性20例,年龄60~75岁、平均年龄(62.17±7.03)岁,糖尿病病程8~21年、平均病程(10.78±2.80)年,并发症:4例合并胃轻瘫,2例合并糖尿病足,18例合并周围神经病变,27例合并视网膜病变。2组一般资料比较差异无统计学意义(P>0.05),具有可比性。1.1 General information A total of 64 patients with type 2 diabetic nephropathy of yin and yang deficiency with blood stasis and phlegm from January 2016 to February 2018 in the Diabetes Department of Shantou Hospital of Traditional Chinese Medicine were selected and randomly divided into the control group and the observation group. , 32 cases in each group. In the control group, there were 15 males and 17 females; aged 61-72 years, mean age (66.89±5.13) years, duration of diabetes mellitus 10-20 years, mean duration (10.26±2.75) years, complications (some patients combined 2 or 2 or more complications), 3 with gastroparesis, 3 with diabetic foot, 19 with peripheral neuropathy, and 28 with retinopathy. The observation group included 18 males and 20 females, aged 60-75 years, average age (62.17±7.03) years, diabetes duration 8-21 years, mean duration (10.78±2.80) years, complications: 4 cases with gastroparesis , 2 cases with diabetic foot, 18 cases with peripheral neuropathy, 27 cases with retinopathy. There was no significant difference in general data between the two groups (P>0.05), which was comparable.
1.2诊断与辨证标准 西医诊断标准:按1999年WHO诊断和分类标准进行糖尿病诊断和分型。中医辨证标准:口干咽燥,五心烦热,面色苍白,神疲乏力,畏寒肢凉,面目及肢体浮肿,小便频数,夜尿增多,浑浊如脂如膏,甚至饮一溲一,面色黧黑,腰膝酸软,脘腹胀满,食纳不香,阳痿,五更泄泻,舌淡体胖苔白而干,脉沉细无力。1.2 Diagnosis and differentiation criteria Western medicine diagnostic criteria: Diagnosis and classification of diabetes according to the 1999 WHO diagnostic and classification criteria. TCM Syndrome Differentiation Criteria: Dry mouth and throat, vexation and heat in the five hearts, pale complexion, mental fatigue, aversion to cold and cold limbs, swelling of the face and limbs, frequent urination, increased nocturia, turbidity as fat as ointment, and even drinking a fen yi, complexion Mucuna black, sore waist and knees, fullness in the abdomen and abdomen, poor appetite, impotence, diarrhea, pale tongue, fat body, white and dry coating, thin and weak pulse.
1.3纳入标准 (1)符合2型糖尿病诊断标准;(2)中医辨证主证属于阴阳两虚夹瘀、痰可以使用健脾通阳方治疗的患者。1.3 Inclusion criteria (1) Meet the diagnostic criteria for type 2 diabetes; (2) The main syndrome of TCM syndrome differentiation belongs to patients with yin and yang deficiency with blood stasis and phlegm that can be treated with Jianpi Tongyang prescription.
1.4排除标准 (1)排除住院诊断合并心肌炎、心包病及其他器质性心脏病、电解质失调等心脏疾病者;(2)合并有严重心脑血管及肝功能损害患者,或者近期出现糖尿病酮症、高渗性昏迷者;(3)妊娠、过敏等不适合于接受本治疗方案者;(4)年龄大于75岁者;(5)资料采集期间生活方式发生较大变化,可能影响研究结果的分析的患者;(6)不合作者。1.4 Exclusion criteria (1) Exclude hospitalized patients with myocarditis, pericardial disease, other organic heart disease, electrolyte imbalance and other heart diseases; (2) Patients with severe cardiovascular and cerebrovascular and liver damage, or recent diabetic ketosis , hyperosmotic coma; (3) pregnancy, allergies, etc. who are not suitable for this treatment plan; (4) those who are older than 75 years old; (5) major changes in lifestyle during data collection, which may affect the results of the study Analyzed patients; (6) non-cooperators.
2方法2 methods
2.1治疗方法两组均给予糖尿病综合治疗,即健康教育、饮食管理、运动管理、血糖监测及管理等,对于出现合并症者给予针对性干预。对照组加用开博通治疗(国药准字H31022986,上海施贵宝制药),口服,12.5mg/次,2~3次/d。观察组加用本发明实施例1的健脾通阳方治疗,水煎服,日1剂,煎煮成400mL,每次200mL,早晚2次温服,治疗2月后统计治疗结果。2.1 Treatment methods Both groups were given comprehensive diabetes treatment, namely health education, diet management, exercise management, blood glucose monitoring and management, etc., and targeted interventions were given to those with comorbidities. The control group was additionally treated with Kaibotong (National Medicine Zhunzi H31022986, Shanghai Squibb Pharmaceuticals), orally, 12.5 mg/time, 2-3 times/d. The observation group was additionally treated with the Jianpi Tongyang formula of Example 1 of the present invention, decocted in water, 1 dose a day, decocted into 400 mL, 200 mL each time, warmed twice in the morning and evening, and the treatment results were counted after 2 months of treatment.
2.2观察指标2.2 Observation indicators
2.2.1安全评价标准 一般体格检查:血压、呼吸、脉搏、体温。②血尿便常规检查。2.2.1 Safety evaluation criteria General physical examination: blood pressure, respiration, pulse, body temperature. ② Routine examination of hematuria and stool.
2.2.2疗效性观察 空腹及餐后2h血糖、糖化血红蛋白、血压、24小时尿白蛋白定量,中医临床症状与体征,治疗前、治疗后各评估1次。2.2.2 Efficacy observation Fasting and postprandial 2h blood glucose, glycosylated hemoglobin, blood pressure, 24-hour urine albumin quantification, TCM clinical symptoms and signs, before and after treatment were evaluated once.
2.3统计学处理 本研究中的相关数据选择统计学软件SPSS 18.0展开统计学处理,以均数±标准差表示计量资料,采用t检验;采用卡方检验,P<0.05则表示组间计数资料对比差异性较为显著,存在统计学意义。2.3 Statistical processing Statistical software SPSS 18.0 was used for statistical processing of relevant data in this study, measurement data were expressed as mean ± standard deviation, and t-test was used; Chi-square test was used, and P<0.05 indicated a comparison of count data between groups The difference is more significant and there is statistical significance.
3结果3 results
3.1治疗前后2组患者血糖、血压比较治疗前2组患者的空腹血糖、餐后2h血糖、HbA1c、血压(收缩压、舒张压)比较差异没有统计学意义(P>0.05)。治疗后上述指标显著低于治疗前(P均<0.05),但两组间差异无显著性意义(P均>0.05)(表1)。表明两组患者的一般情况相似,具有较好的可比性,治疗后血糖和血压都得到了有效控制。3.1 Comparison of blood glucose and blood pressure between the two groups before and after treatment There was no significant difference in fasting blood glucose, 2h postprandial blood glucose, HbA1c, and blood pressure (systolic blood pressure, diastolic blood pressure) between the two groups before treatment (P>0.05). After treatment, the above indexes were significantly lower than those before treatment (all P<0.05), but there was no significant difference between the two groups (all P>0.05) (Table 1). It shows that the general conditions of the two groups of patients are similar and have good comparability, and both blood sugar and blood pressure have been effectively controlled after treatment.
表1 两组治疗前后血糖、糖化血红蛋白及血压比较Table 1 Comparison of blood glucose, glycosylated hemoglobin and blood pressure between the two groups before and after treatment
注:
★与治疗前相比,P<0.05。
Note: ★ P<0.05 compared with before treatment.
3.2治疗前后2组患者24h尿蛋白定量比较治疗前2组尿白蛋白定量无明显差异(P>0.05)。治疗后两组尿蛋白定量均明显低于治疗前,其差异有显著性意义(P均<0.01);治疗后健脾通阳方治疗组与对照组比较,治疗组尿蛋白定量显著低于对照组,差异具有统计学意义(P均<0.01)(表2)。表明健脾通阳方及开博通均可有效减少尿白蛋白排出,但健脾通阳方减少尿蛋白排泄的功效优于开博通。3.2 Comparison of 24h urine protein quantitative comparison between the two groups before and after treatment There was no significant difference in urine albumin quantitative between the two groups before treatment (P>0.05). After treatment, the urine protein quantification of the two groups was significantly lower than that before treatment, and the difference was significant (P<0.01). group, the difference was statistically significant (P<0.01) (Table 2). It shows that both Jianpi Tongyang prescription and Kaibotong can effectively reduce urinary albumin excretion, but Jianpitongyang prescription is better than Kaibotong in reducing urinary protein excretion.
表2 两组治疗前后尿蛋白比较(mg/24h)Table 2 Urine protein comparison between the two groups before and after treatment (mg/24h)
注:
★治疗前与治疗后比较,P<0.01;
●治疗组与对照组治疗后比较P<0.05。
Note: ★ Comparison before treatment and after treatment, P<0.01; ● Comparison between treatment group and control group after treatment, P<0.05.
3.3 2组患者不良反应比较两组未出现肝功能异常,肾功能不全进一步加重,糖尿病酮症酸中毒、低血糖昏迷等急性并发症。3.3 Comparison of adverse reactions of patients in the two groups There was no abnormal liver function, further aggravation of renal insufficiency, acute complications such as diabetic ketoacidosis and hypoglycemia coma in the two groups.
3.结论3. Conclusion
糖尿病属于中医学“消渴”范畴,古代中医学多从“阴虚燥热”论治。然而,现今临床发现不论是病因病机与发病,还是临床表现,乃至治疗方法,都已发生变化。临床实践表明,健脾通阳方治疗阴阳两虚夹痰、瘀型糖尿病,不仅降糖效果确切,使用安全,而且在降低尿蛋白,减轻糖尿病引起的症状上较之西药治疗更有优势。Diabetes belongs to the category of "diabetes" in traditional Chinese medicine, and ancient traditional Chinese medicine mostly treats it from "dryness and heat due to yin deficiency". However, the current clinical findings have changed in terms of etiology, pathogenesis and pathogenesis, clinical manifestations, and even treatment methods. Clinical practice shows that Jianpi Tongyang Recipe in the treatment of yin and yang deficiency with phlegm and blood stasis type diabetes not only has an exact hypoglycemic effect and is safe to use, but also has advantages over western medicine in reducing urinary protein and alleviating symptoms caused by diabetes.
二、治疗慢性肾功能不全的临床研究2. Clinical research on the treatment of chronic renal insufficiency
1.一般资料与方法1. General information and methods
1.1病例来源1.1 Case source
随机选取2016年1月到2018年12月在汕头市中医院糖尿病科门诊就诊及住院病房收治的符合条件的慢性肾功能不全(CRF)患者60例。A total of 60 eligible patients with chronic renal insufficiency (CRF) who were admitted to the outpatient clinic and inpatient ward of the Diabetes Department of Shantou Hospital of Traditional Chinese Medicine from January 2016 to December 2018 were randomly selected.
1.2病例分组1.2 Case grouping
在确诊的慢性肾功能不全患者中,将入选的60例患者按1:1比例随机分为2组,即中药组,对照组。将两组性别、年龄等一般资料进行比较,应用SPSS软件,经卡方检验比较后,确定是否具有可比性(无显著性差异P>0.05)。Among the diagnosed patients with chronic renal insufficiency, the selected 60 patients were randomly divided into 2 groups according to the ratio of 1:1, namely the traditional Chinese medicine group and the control group. The gender, age and other general data of the two groups were compared, and SPSS software was used to determine whether they were comparable (no significant difference P>0.05).
1.3病例诊断标准1.3 Diagnostic criteria for cases
1.3.1西医诊断标准:参照《内科学》,将CRF分为四期:①肾功能代偿期:肌酐清除率(CCr)50~80mL/min,血肌酐(SCr)133~177umol/L;②肾功能失代偿期:CCr20~50mL/min,SCr 186~442umo1/L:③肾功能衰竭期:CCr 10~20mL/min,SCr 451~707umol/L;④尿毒症期:CCr<10mL/min,SCr>707umo1/L。1.3.1 Western medicine diagnostic criteria: referring to Internal Medicine, CRF is divided into four stages: ① renal function compensation stage: creatinine clearance (CCr) 50~80mL/min, serum creatinine (SCr) 133~177umol/L; ②Renal decompensation stage: CCr 20~50mL/min, SCr 186~442umol/L: ③ Renal failure stage: CCr 10~20mL/min, SCr 451~707umol/L; ④ Uremia stage: CCr<10mL/ min, SCr>707umo1/L.
其中①~③为早中期。Among them, ① to ③ are the early and middle stages.
1.3.2中医诊断标准1.3.2 TCM diagnostic criteria
中医诊断标准参照2002年中华人民共和国卫生部出版的《中药新药临床研究指导原则》及《中医内科学》(普通高等教育中医药类规划教材)。The diagnostic criteria of traditional Chinese medicine refer to "Guidelines for Clinical Research of New Chinese Medicines" and "Internal Medicine of Traditional Chinese Medicine" published by the Ministry of Health of the People's Republic of China in 2002 (traditional Chinese medicine planning textbooks for general higher education).
中医辨证标准:中医辨证为阴阳两虚夹瘀、痰证。主症:畏寒肢冷,倦怠乏力,气短懒言,食少纳呆,腰膝酸软。次症:腰部冷痛,脘腹胀满,大便不实,夜尿清长,舌淡有齿痕,脉沉弱。TCM syndrome differentiation standard: TCM syndrome differentiation is yin and yang deficiency with blood stasis and phlegm syndrome. Main symptoms: chills and cold extremities, fatigue, shortness of breath, sluggishness, lack of appetite, soreness and weakness of the waist and knees. Secondary symptoms: cold pain in the waist, abdominal distention, loose stools, clear and long nocturnal urination, pale tongue with tooth marks, and weak pulse.
1.4.病例的纳入及排除标准1.4. Inclusion and exclusion criteria of cases
1.4.1纳入标准:①符合上述西医诊断标准及中医辨证标准者;②无对本研究药物过敏史;③年龄30~87岁;④患者均自愿参与并签署知情同意书,具有良好的依从性。1.4.1 Inclusion criteria: ① Those who meet the above-mentioned Western medicine diagnostic criteria and TCM syndrome differentiation criteria; ② No history of allergy to the drugs in this study; ③ Age 30-87 years old; ④ All patients participated voluntarily and signed the informed consent form, with good compliance.
1.4.2排除标准:①CRF尿毒症期;②妊娠或哺乳期妇女;③近1个月使用激素等免疫抑制剂,肾移植手术史;④伴有心、脑、肝脏和造血系统等严重原发疾病;⑤已进行血液透析及肾脏移植;⑥依从性差,不能按要求完成治疗。1.4.2 Exclusion criteria: ① CRF uremic stage; ② Pregnant or lactating women; ③ Use of hormones and other immunosuppressants in the past 1 month, history of kidney transplantation; ④ Accompanied by serious primary diseases such as heart, brain, liver and hematopoietic system 5. Hemodialysis and kidney transplantation have been performed. 6. Poor compliance and unable to complete the treatment as required.
1.4.3剔除及脱落标准:符合入选标准,并且已经分组,但因各种原因未实施任何治疗的患者,或因各种原因未按规定完成治疗与对照观察者,疗效观察记录不完整者。1.4.3 Elimination and dropout criteria: patients who meet the inclusion criteria and have been grouped, but have not received any treatment for various reasons, or who have not completed the treatment and control observations as required for various reasons, and who have incomplete efficacy observation records.
1.5研究方法:对照组予优质低蛋白饮食。蛋白摄取量按肌酐清除率确定,若饮食摄入蛋白量不足时,可予适量必需氨基酸(口服或静脉滴注)。对症予抗感染、纠正酸中毒、降压、纠正电解质紊乱等治疗。中药组在对照组基础上予实施例1的健脾通阳方,水煎服,每日1剂,煎煮成400mL,每次200mL,早晚2次温服,4周为1个疗程,2个疗程后统计治疗结果。1.5 Research methods: The control group was given a high-quality low-protein diet. The protein intake is determined according to the creatinine clearance rate. If the dietary protein intake is insufficient, an appropriate amount of essential amino acids can be given (oral or intravenous drip). Symptomatic treatment of anti-infection, correction of acidosis, antihypertensive, correction of electrolyte imbalance, etc. was given. On the basis of the control group, the Chinese medicine group was given the Jianpi Tongyang formula of Example 1, decocted in water, 1 dose per day, decocted into 400mL, 200mL each time, warmed twice in the morning and evening, 4 weeks as a course of treatment, 2 Statistical treatment results after a course of treatment.
1.6.观察方法1.6. Observation method
1.6.1观察指标1.6.1 Observation indicators
1.6.1.1安全评价标准1.6.1.1 Safety Evaluation Criteria
①一般体格检查:血压、呼吸、脉搏、体温。②血常规、尿常规、肝肾功能、血钾。①General physical examination: blood pressure, respiration, pulse, body temperature. ② blood, urine, liver and kidney function, serum potassium.
1.6.1.2疗效性观察。1.6.1.2 Observation of curative effect.
①SCr、血尿素氮(BUN)、胱抑素C(Cys-C)、尿微量白蛋白(UAER)、24小时尿蛋白定量、高密度脂蛋白 胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、甘油三脂(TG)、总胆固醇(CHOL)等。①SCr, blood urea nitrogen (BUN), cystatin C (Cys-C), urine microalbumin (UAER), 24-hour urine protein quantification, high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol ( LDL-C), triglyceride (TG), total cholesterol (CHOL), etc.
②中医临床症状与体征,治疗前、治疗2月后各评估1次。②The clinical symptoms and signs of traditional Chinese medicine were evaluated once before treatment and once after 2 months of treatment.
1.7疗效评定标准1.7 Efficacy evaluation criteria
1.7.1临床疗效标准1.7.1 Clinical efficacy criteria
参照《慢性肾衰竭的诊断、辨证分型及疗效评定(试行方案)》及临床经验制定。显效:①症状减轻或消失;②BUN下降≥30%;③SCr降低≥30%。有效:①症状减轻或消失;②BUN下降≥20%;③SCr降低≥20%;以上①项必备,②③具备1项即可判定。稳定:症状改善及BUN、SCr未见恶化或略下降。无效:治疗前后自觉症状和体征不减轻或加重,BUN、SCr无明显改善或较治疗前反而升高。It was formulated with reference to "Diagnosis, Syndrome Differentiation and Efficacy Evaluation of Chronic Renal Failure (Trial Scheme)" and clinical experience. Markedly effective: ① Symptoms relieved or disappeared; ② BUN decreased by ≥30%; ③ SCr decreased by ≥30%. Effective: ① symptoms relieved or disappeared; ② BUN decreased by ≥ 20%; ③ SCr decreased by ≥ 20%; the above ① items are required, and ②③ can be judged if one item is present. Stable: Symptoms improved and BUN and SCr did not worsen or decreased slightly. Ineffective: The subjective symptoms and signs did not relieve or aggravate before and after treatment, and BUN and SCr did not improve significantly or were higher than before treatment.
1.7.2中医疗效标准1.7.2 The efficacy standard of traditional Chinese medicine
参照《中药新药临床研究指导原则(试行)》制定。临床痊愈:中医症状消失或基本消失,积分减少率≥95%;显效:中医症状减轻,70%≤积分减少率<95%;有效:中医症状减轻,30%≤积分减少率<70%;无效:临床症状无改善,积分减少率<30%。积分减少率(%)=(治疗前积分-治疗后积分)÷治疗前积分×100%It was formulated with reference to the "Guiding Principles for Clinical Research on New Chinese Medicines (Trial)". Clinical recovery: TCM symptoms disappeared or basically disappeared, and the score reduction rate was ≥95%; markedly effective: TCM symptoms were relieved, 70%≤integral reduction rate <95%; Effective: TCM symptoms were relieved, 30%≤integral reduction rate <70%; : There is no improvement in clinical symptoms, and the score reduction rate is less than 30%. Point reduction rate (%) = (points before treatment - points after treatment) ÷ points before treatment × 100%
1.8统计学处理 本研究中的相关数据选择统计学软件SPSS 18.0展开统计学处理,以均数±标准差表示计量资料,采用t检验;采用卡方检验,P<0.05则表示组间计数资料对比差异性较为显著,存在统计学意义。1.8 Statistical processing The statistical software SPSS 18.0 was used for statistical processing of the relevant data in this study. The measurement data were expressed as mean ± standard deviation, and t test was used; The difference is more significant and there is statistical significance.
2结果2 results
2.1治疗前后2组患者肾功能指标比较 2组患者治疗前的尿素氮(BUN)、血肌酐(Scr)和肾小球滤过率(eGFR)比较差异没有统计学意义(P>0.05)。2组患者在治疗后的尿素氮、血肌酐均有所下降,治疗前后对比差异性有统计学意义(P<0.05),治疗后健脾通阳方组患者尿素氮(BUN)、血肌酐(Scr)和肾小球滤过率(eGFR)明显优于对照组患者(P<0.05),存在统计学意义,见表3。2.1 Comparison of renal function indexes between the two groups before and after treatment There was no significant difference in blood urea nitrogen (BUN), serum creatinine (Scr) and glomerular filtration rate (eGFR) between the two groups before treatment (P>0.05). The blood urea nitrogen (BUN), serum creatinine (BUN), serum creatinine (BUN), serum creatinine ( Scr) and glomerular filtration rate (eGFR) were significantly better than those in the control group (P<0.05), with statistical significance, see Table 3.
表3 两组治疗前后肾功能指标比较(n=30)Table 3 Comparison of renal function indexes between the two groups before and after treatment (n=30)
注:★与治疗前相比,P<0.05;●与对照组相比,P<0.05Note: ★Compared with before treatment, P<0.05; ●Compared with control group, P<0.05
2.2治疗前后2组患者尿白蛋白、24小时尿蛋白定量比较2组患者治疗前的餐后尿白蛋白、24小时尿蛋白定量比较差异没有统计学意义(P>0.05)。2组患者在治疗后的尿白蛋白、24小时尿蛋白定量均有所下降,治疗前后对比差异性有统计学意义(P<0.05),治疗后健脾通阳组患者尿白蛋白、24小时尿蛋白定量水平明显优于对照组患者(P<0.05),存在统计学意义,见表4。2.2 Before and after treatment, there was no significant difference in the quantitative comparison of postprandial urine albumin and 24-hour urine protein between the two groups before and after treatment (P>0.05). After treatment, the urinary albumin and 24-hour urine protein quantification of patients in both groups decreased, and the difference was statistically significant before and after treatment (P<0.05). The quantitative level of urinary protein was significantly better than that of the control group (P<0.05), with statistical significance, as shown in Table 4.
表4 两组治疗前后尿白蛋白、24小时尿蛋白定量比较(n=30)Table 4 Quantitative comparison of urinary albumin and 24-hour urinary protein between the two groups before and after treatment (n=30)
注:★与治疗前相比,P<0.05;●与对照组相比,P<0.05Note: ★Compared with before treatment, P<0.05; ●Compared with control group, P<0.05
2.3 2组患者中医症状评分比较 治疗后健脾通阳方组患者的中医症状疗效评估善明显优于对照组,差异有统计学意义(P<0.05),见表5。2.3 Comparison of TCM symptom scores between the two groups After treatment, the efficacy evaluation of TCM symptoms in the Jianpi Tongyang prescription group was significantly better than that in the control group, and the difference was statistically significant (P<0.05), as shown in Table 5.
表5 治疗后中医疗效评估比较Table 5 Comparison of TCM efficacy evaluation after treatment
注:★与对照组比较,P<0.05Note: ★Compared with the control group, P<0.05
2.4 2组患者不良反应比较 健脾通阳方组有3例服中药后出现嗳气反酸,3例咽喉疼痛,3例便秘;对照组有4例出现腹痛腹胀,持续时间5天到7天,均经对症处理后可以完成治疗。两组未出现肝功能异常,糖尿病酮症酸中毒、低血糖昏迷等急性并发症。2.4 Comparison of adverse reactions of patients in the two groups In the Jianpi Tongyang Recipe group, 3 patients had belching and acid reflux, 3 patients had sore throat, and 3 patients had constipation; Treatment can be completed after symptomatic treatment. There were no acute complications such as abnormal liver function, diabetic ketoacidosis, hypoglycemia and coma in the two groups.
3.结论3. Conclusion
慢性肾功能不全属中医学“关格”“虚劳”“水肿”“腰痛”等范畴。本病病机复杂,既有正气亏虚,又有邪实内蕴,属本虚标实、虚实夹杂之证。多数中医家认为本病以脾肾阴阳两虚为基本病机,而瘀、湿、浊贯穿于整个病程之中。Chronic renal insufficiency belongs to the categories of "guange", "consumption", "edema" and "low back pain" in traditional Chinese medicine. The pathogenesis of this disease is complex, with both the deficiency of righteousness and the inner connotation of evil. Most Chinese medicine practitioners believe that the basic pathogenesis of this disease is deficiency of yin and yang of the spleen and kidney, and blood stasis, dampness and turbidity run through the entire course of the disease.
临床实践表明,本发明的健脾通阳方联合常规对症疗法对阴阳两虚夹瘀、痰证CRF患者治疗效果较好,可缓解患者中医证候,并改善其肾功能,在延缓慢性肾脏疾病进展方面较之单纯西药治疗更有优势。Clinical practice shows that the Jianpi Tongyang prescription of the present invention combined with conventional symptomatic therapy has a better therapeutic effect on patients with CRF due to yin and yang deficiency and phlegm syndrome, can alleviate the patient's traditional Chinese medicine syndrome, and improve their renal function, and is effective in delaying chronic kidney disease. In terms of progress, it has more advantages than simple western medicine treatment.
Claims (9)
- 一种健脾通阳中药组合物,其特征在于:按重量份数计算,配方由以下组分组成:葛根12-18份、丹参12-18份、白术25-35份、党参25-35份、黄柏4-6份、川芎12-18份、田七8-12份、桂枝8-12份、仙灵脾12-18份、肉苁蓉25-35份、山茱萸12-18份、干姜8-12份、苍术12-18份。A traditional Chinese medicine composition for strengthening spleen and activating yang, characterized in that: calculated in parts by weight, the formula is composed of the following components: 12-18 parts of Pueraria lobata, 12-18 parts of Salvia miltiorrhiza, 25-35 parts of Atractylodes Rhizoma, and 25-35 parts of Codonopsis Radix , 4-6 parts of Treats, 12-18 parts of Chuanxiong, 8-12 parts of Tianqi, 8-12 parts of Guizhi, 12-18 parts of Xianlingpi, 25-35 parts of Cistanche, 12-18 parts of dogwood, 8 parts of dried ginger -12 copies, Atractylodes 12-18 copies.
- 根据权利要求1所述的健脾通阳中药组合物,其特征在于:按重量份数计算,配方由以下组分组成:葛根14-16份、丹参14-16份、白术28-32份、党参28-32份、黄柏4-6份、川芎14-16份、田七9-11份、桂枝9-11份、仙灵脾14-16份、肉苁蓉28-32份、山茱萸14-16份、干姜9-11份、苍术14-16份。。The traditional Chinese medicine composition for strengthening the spleen and activating yang according to claim 1, is characterized in that: calculated in parts by weight, the formula is made up of the following components: 14-16 parts of Pueraria lobata, 14-16 parts of Salvia miltiorrhiza, 28-32 parts of Atractylodes Rhizoma, Codonopsis 28-32 parts, Treats 4-6 parts, Chuanxiong 14-16 parts, Tianqi 9-11 parts, Guizhi 9-11 parts, Xianlingpi 14-16 parts, Cistanche deserticola 28-32 parts, Cornus 14-16 parts servings, 9-11 servings of dried ginger, and 14-16 servings of Atractylodes. .
- 根据权利要求1所述的健脾通阳中药组合物,其特征在于:按重量份数计算,配方由以下组分组成:葛根15份、丹参15份、白术30份、党参30份、黄柏5份、川芎15份、田七10份、桂枝10份、仙灵脾15份、肉苁蓉30份、山茱萸15份、干姜10份、苍术15份。The traditional Chinese medicine composition for strengthening the spleen and activating yang according to claim 1, is characterized in that: calculated in parts by weight, the formula is made up of the following components: 15 parts of Pueraria lobata, 15 parts of Salvia miltiorrhiza, 30 parts of Atractylodes Rhizoma, 30 parts of Codonopsis Radix, 5 parts of Cork Phellodendri 15 parts of Chuanxiong, 10 parts of Tianqi, 10 parts of Guizhi, 15 parts of Xianlingpi, 30 parts of Cistanche, 15 parts of dogwood, 10 parts of dried ginger, and 15 parts of Atractylodes.
- 权利要求1-3任一权利要求所述健脾通阳中药组合物在制备治疗糖尿病、糖尿病肾病、慢性肾功能不全的药物的应用。Application of the traditional Chinese medicine composition for strengthening spleen and yang in any one of claims 1 to 3 in the preparation of medicines for the treatment of diabetes, diabetic nephropathy and chronic renal insufficiency.
- 根据权利要求4所述的应用,其特征在于:所述的药物为汤剂、颗粒剂、片剂、胶囊剂、口服液或丸剂。Application according to claim 4, is characterized in that: described medicine is decoction, granule, tablet, capsule, oral liquid or pill.
- 根据权利要求4所述的应用,其特征在于:所述的药物为以所述健脾通阳中药组合物配方中组分的提取物为有效成分,添加药用辅料制得的制剂。The application according to claim 4, wherein the medicine is a preparation prepared by adding medicinal excipients with extracts of the components in the formula of the Chinese medicine composition for strengthening spleen and yang as active ingredients.
- 根据权利要求6所述的应用,其特征在于:所述的提取物为水提取物。The application according to claim 6, wherein the extract is a water extract.
- 根据权利要求4所述的应用,其特征在于:所述的糖尿病是糖尿病后期。The application according to claim 4, wherein the diabetes is late diabetes.
- 根据权利要求4所述的应用,其特征在于:所述的糖尿病、糖尿病肾病、慢性肾功能不全是阴阳两虚夹瘀、痰型的糖尿病、糖尿病肾病、慢性肾功能不全。The application according to claim 4, wherein the diabetes, diabetic nephropathy, and chronic renal insufficiency are phlegm-type diabetes, diabetic nephropathy, and chronic renal insufficiency.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010743269.4 | 2020-07-29 | ||
CN202010743269.4A CN111729064A (en) | 2020-07-29 | 2020-07-29 | Traditional Chinese medicine composition for invigorating spleen and activating yang and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022021639A1 true WO2022021639A1 (en) | 2022-02-03 |
Family
ID=72656426
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2020/124369 WO2022021639A1 (en) | 2020-07-29 | 2020-10-28 | Traditional chinese medicine composition for invigorating spleen and activating yang, and use thereof |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN111729064A (en) |
WO (1) | WO2022021639A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115487283A (en) * | 2022-09-27 | 2022-12-20 | 李海霞 | Chinese medicinal preparation for treating heart failure |
CN117414351A (en) * | 2023-11-14 | 2024-01-19 | 中国中医科学院西苑医院 | Traditional Chinese medicine patch for treating spleen-kidney yang deficiency constipation and preparation method and application thereof |
CN117482131A (en) * | 2023-10-26 | 2024-02-02 | 北京中医药大学东直门医院 | Traditional Chinese medicine composition for treating chronic kidney disease and application thereof |
CN117653701A (en) * | 2023-12-25 | 2024-03-08 | 江西天元药业有限公司 | Composition for treating male sexual dysfunction |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111729064A (en) * | 2020-07-29 | 2020-10-02 | 汕头市中医医院 | Traditional Chinese medicine composition for invigorating spleen and activating yang and application thereof |
CN117224645B (en) * | 2023-10-24 | 2024-08-30 | 江苏省中医院 | Traditional Chinese medicine compound composition for treating diabetic nephropathy and preparation method and application thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106138283A (en) * | 2016-08-31 | 2016-11-23 | 李赛美 | A kind of drug regimen treating diabetes B |
CN111658701A (en) * | 2020-07-14 | 2020-09-15 | 汕头市中医医院 | Spleen-tonifying traditional Chinese medicine composition and application thereof |
CN111729064A (en) * | 2020-07-29 | 2020-10-02 | 汕头市中医医院 | Traditional Chinese medicine composition for invigorating spleen and activating yang and application thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100522192C (en) * | 2006-10-16 | 2009-08-05 | 北京亚东生物制药有限公司 | Method for preparing Chinese medicine particles for treating cardio-cerebral vascular diseases and its product |
-
2020
- 2020-07-29 CN CN202010743269.4A patent/CN111729064A/en not_active Withdrawn
- 2020-10-28 WO PCT/CN2020/124369 patent/WO2022021639A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106138283A (en) * | 2016-08-31 | 2016-11-23 | 李赛美 | A kind of drug regimen treating diabetes B |
CN111658701A (en) * | 2020-07-14 | 2020-09-15 | 汕头市中医医院 | Spleen-tonifying traditional Chinese medicine composition and application thereof |
CN111729064A (en) * | 2020-07-29 | 2020-10-02 | 汕头市中医医院 | Traditional Chinese medicine composition for invigorating spleen and activating yang and application thereof |
Non-Patent Citations (2)
Title |
---|
CHEN QIUMING, CHEN CHAO, WU BANGTAI: "Clinical Application of Spleen and Stomach Theory for Diabetes Treatment", GUANGMING-ZHONGYI = GUANGMING JOURNAL OF CHINESE MEDICINE, ZHONGHUA ZHONGYIYAO XUEHUI ZHUBAN. GUANGMING-ZHONGYI ZAZHE BIANJIBU BIANJI, CN, vol. 34, no. 23, 31 December 2019 (2019-12-31), CN , pages 3556 - 3558, XP055886773, ISSN: 1003-8914, DOI: 10.3969/j.issn.1003-8914.2019.23.009 * |
WANG XUHUANG, GUO YUAN-YUAN;XIE XI;WU BANG-TAI;XU XU-YUN;JI SHU-PING;GU JIE-MIN;CHEN CHAO: "Effect of Jianpi Huoluo Formula on Treating Diabetic Distal Symmetric Polyneuropathy Differentiated by Spleen Deficiency and Blood Stasis", WORLD JOURNAL OF INTEGRATED TRADITIONAL AND WESTERN MEDICINE, vol. 15, no. 3, 31 March 2020 (2020-03-31), pages 535 - 538, XP055891285, DOI: 10.13935/j.cnki.sjzx.200332 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115487283A (en) * | 2022-09-27 | 2022-12-20 | 李海霞 | Chinese medicinal preparation for treating heart failure |
CN115487283B (en) * | 2022-09-27 | 2024-01-02 | 李海霞 | Traditional Chinese medicine preparation for treating heart failure |
CN117482131A (en) * | 2023-10-26 | 2024-02-02 | 北京中医药大学东直门医院 | Traditional Chinese medicine composition for treating chronic kidney disease and application thereof |
CN117414351A (en) * | 2023-11-14 | 2024-01-19 | 中国中医科学院西苑医院 | Traditional Chinese medicine patch for treating spleen-kidney yang deficiency constipation and preparation method and application thereof |
CN117414351B (en) * | 2023-11-14 | 2024-03-15 | 中国中医科学院西苑医院 | Traditional Chinese medicine patch for treating spleen-kidney yang deficiency constipation and preparation method and application thereof |
CN117653701A (en) * | 2023-12-25 | 2024-03-08 | 江西天元药业有限公司 | Composition for treating male sexual dysfunction |
Also Published As
Publication number | Publication date |
---|---|
CN111729064A (en) | 2020-10-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2022021639A1 (en) | Traditional chinese medicine composition for invigorating spleen and activating yang, and use thereof | |
WO2022021637A1 (en) | Spleen-strengthening and kidney-tonifying traditional chinese medicine composition and application thereof | |
WO2022011880A1 (en) | Spleen strengthening traditional chinese medicine composition and application thereof | |
WO2022021638A1 (en) | Traditional chinese medicinal composition for invigorating spleen and removing turbidity and application thereof | |
WO2022021636A1 (en) | Traditional chinese medicine composition for invigorating spleen and activating collaterals, and use thereof | |
CN101125177B (en) | Fermented glutinous wine for treating diabetes | |
CN101897933B (en) | Chinese patent medicament for treating leucoderma | |
CN114917310B (en) | Traditional Chinese medicine for treating 3-5 stages of chronic kidney disease and preparation method thereof | |
CN115252753A (en) | Traditional Chinese medicine composition for treating insomnia and application thereof | |
CN112675271A (en) | Traditional Chinese medicine composition for treating internal abnormality and application thereof | |
CN117018105B (en) | Traditional Chinese medicine composition for treating impaired glucose tolerance and preparation method thereof | |
CN111603506A (en) | Application of stomach-regulating qi-supporting decoction in preparation of medicine for preventing and treating metabolic syndrome caused by olanzapine taken by schizophrenia patient | |
CN111135247A (en) | Traditional Chinese medicine for treating stage IV diabetic nephropathy | |
CN115137785B (en) | Membranous kidney prescription for treating idiopathic membranous nephropathy | |
CN104288579A (en) | Traditional Chinese medicine for treating chronic nephritis and preparation method thereof | |
CN104225016A (en) | Drug composition for treating spleen and stomach deficiency type chronic atrophic gastritis | |
CN114191514B (en) | Traditional Chinese medicine composition for preventing and treating phlegm-damp type obesity | |
CN107468849A (en) | A kind of medicine for treating chronic renal failure and preparation method thereof | |
CN102233004B (en) | Drug for treating liver diseases | |
CN105943860A (en) | Medicine preparation for treating diabetes mellitus and preparation method thereof | |
CN113304220A (en) | Traditional Chinese medicine composition and traditional Chinese medicine mixture for treating deficiency syndrome in traditional Chinese medicine | |
CN116115710A (en) | Traditional Chinese medicine composition for protecting liver and stomach, tonifying deficiency and reducing blood glucose | |
CN114504626A (en) | She medicine formula for treating H-type hypertension phlegm-blood stasis syndrome | |
CN118593615A (en) | Kidney-tonifying and primordial qi-strengthening decoction traditional Chinese medicine composition for delaying kidney fibrosis | |
CN115645507A (en) | Pure traditional Chinese medicine composition for treating obese type 2 diabetes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20946754 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20946754 Country of ref document: EP Kind code of ref document: A1 |